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Abstract
Epithelial-Mesenchymal transition (EMT) of primary tumor cells is a critical trans-differentiation event that
contributes to dissemination and metastasis of solid tumors. The process of EMT is controlled by
specific DNA-binding transcription factors (TFs) that reprogram the tumor transcriptome. In particular, the
canonical EMT-TFs Twist and Snail can induce an EMT program when overexpressed in cancer cells, and
both are found upregulated in metastatic cancers. Twist and Snail bind DNA directly, by recognition to
variants of the E-Box sequence CANNTG. However, it is unclear how this binding is regulated. We have
used a biochemical approach to dissect DNA binding and protein-protein interactions that occur amongst
these proteins in order to determine the molecular mechanisms of this regulation. We find that Twist
preferentially recognizes a dyad repeat of E-boxes that are not directly bound by Snail. Our data suggest
that Twist use its WR domain to recruit Snail into a binding complex through the Snail zinc-finger motifs.
We analyzed Twist-Snail complexes in the breast carcinoma cell line SUM1315 and found evidence that it
contains an additional protein partner, Sox9. Notably, we report that a native Twist complex can be
displaced from its dyad binding site by consensus DNA binding sites for Snail and Sox9 even though
these proteins do not contact the Twist dyad site. Taken together, our findings suggest that Snail and
Sox9 interact with Twist to regulate its DNA binding ability via protein-protein interactions, thereby
allosterically regulating Twist DNA binding and thereby transcriptional regulation of a broad range of EMT
associated genes by regulation of this binding. We designate this ternary complex EMTosome and have
elucidated the molecular mechanisms by which the DNA binding of it can be regulated. These results may
inform efforts to therapeutically target the EMT program in order to target cancer metastasis.
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ABSTRACT

TWIST, SNAIL, AND SOX9 FORM AN ALLOSTERICALLY REGULATED COMPLEX,
THE EMTOSOME, ON A BIPARTITE E-BOX SITE.
Daniel S. McCracken
Frank J. Rauscher III
Epithelial-Mesenchymal transition (EMT) of primary tumor cells is a critical transdifferentiation event that contributes to dissemination and metastasis of solid tumors.
The process of EMT is controlled by specific DNA-binding transcription factors (TFs) that
reprogram the tumor transcriptome. In particular, the canonical EMT-TFs Twist and Snail
can induce an EMT program when overexpressed in cancer cells, and both are found
upregulated in metastatic cancers. Twist and Snail bind DNA directly, by recognition to
variants of the E-Box sequence CANNTG. However, it is unclear how this binding is
regulated. We have used a biochemical approach to dissect DNA binding and proteinprotein interactions that occur amongst these proteins in order to determine the
molecular mechanisms of this regulation. We find that Twist preferentially recognizes a
dyad repeat of E-boxes that are not directly bound by Snail. Our data suggest that Twist
use its WR domain to recruit Snail into a binding complex through the Snail zinc-finger
motifs. We analyzed Twist-Snail complexes in the breast carcinoma cell line SUM1315
and found evidence that it contains an additional protein partner, Sox9. Notably, we
report that a native Twist complex can be displaced from its dyad binding site by
consensus DNA binding sites for Snail and Sox9 even though these proteins do not
contact the Twist dyad site. Taken together, our findings suggest that Snail and Sox9
interact with Twist to regulate its DNA binding ability via protein-protein interactions,
thereby allosterically regulating Twist DNA binding and thereby transcriptional regulation
iii

of a broad range of EMT associated genes by regulation of this binding. We designate
this ternary complex EMTosome and have elucidated the molecular mechanisms by
which the DNA binding of it can be regulated. These results may inform efforts to
therapeutically target the EMT program in order to target cancer metastasis.
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Chapter 1: Epithelial Mesenchymal Transition and the relationship with cancer
metastasis
Epithelial Mesenchymal Transition and Metastasis

Understanding cancer and the mechanisms by which this broad category of
disease impacts health and life is an ongoing task. One of the most critical mechanisms
by which cancer kills people is by metastasis(1). While the percentage of cancer deaths
due to metastasis varies by type, approximately 75% of breast cancer deaths are due to
metastasis(2).

Since the number of deaths in the United States alone from breast

cancer is over 40,000 every year(3), metastasis accounts for a large number of deaths
worldwide every year.

Every day we are gaining a better understanding of the

underlying mechanisms by which cancerous cells can leave the primary tumor and
colonize distal sites in the body. One of the primary drivers of this process is Epithelial
Mesenchymal Transition (EMT). Gaining a better understanding of this process opens
avenues

to

develop

targets

for

further

research

and

possibly

therapeutic

development(4).
EMT is a genetic regulatory program involved in the differentiation and
dedifferentiation of cells which enables them to become motile (5). This process occurs
during developmental differentiation in many tissues, notably the neural crest, and during
wound healing. Cancer pathobiology often includes reactivation of this program for the
purpose of metastasis, where it provides the motility necessary to leave the primary
tumor, and enter the circulation for distant spread, as well as therapeutic resistance (6).
EMT is regulated on a transcriptional level by a series of proteins, considered master
regulators of EMT. The major transcription factors (TFs), but by no means the only
1

ones, involved in the regulation of EMT are Twist, Snail, Slug, and Zeb (7). Further
understanding of EMT is critical to our understanding of cancer and metastasis, as these
proteins have been shown to be indicators of poor outcomes in cancer treatment (8).

Transcription Factors Regulating Epithelial Mesenchymal Transition

As previously mentioned, the primary TFs which have been shown to be master
regulators of EMT are Twist, Snail, Slug, and Zeb (9).

Together these regulate a

complex series of transcriptional activations and repressions to not only drive the
Mesenchymal phenotype, but also suppress the Epithelial phenotype on a genetic level.
Twist is a transcriptional activator and a type II basic helix-loop-helix (bHLH)
protein that requires an obligate binding partner in order to regulate transcription (10).
This binding partner is typically E12 or E47, both encoded by E2A/TCF3, with which it
forms a dimer of heterodimers, or a tetramer (11). These binding partners are type I
bHLH proteins, and all are part of the HLH protein superfamily (10). Typically type I
bHLH proteins are constitutively expressed, and type II bHLH proteins are differentially
expressed, as is the case for Twist. We have previously discovered that the optimal
Twist binding site occupied in cells is to a dyad E-box (CANNTGNNNNNCANNTG)
binding motif spaced by 5 nucleotides, such as the one in the Alpha-2-macroglobulin
(A2M) gene, in order to regulate transcription (11). We selected this particular DNA
binding site based upon responsiveness to the removal of the WR domain in previous
studies(12).

This allows us to see greater specificity in binding than we would see

utilizing other DNA binding sites for Twist.

As such, our results are specific to this

particular DNA binding site but can be extrapolated to others and validated in future
2

studies. The WR domain of Twist dimerizes Twist, thereby forming a tetramer of TwistE47 molecules on the dyad site. The WR domain also serves as a platform for proteinprotein interactions (PPIs) which occur because of the tetramer binding DNA.

The

bHLH domain of Twist is amino acids 108-164 and the WR domain is amino acids 181194 (Fig 1A).
Snail is a transcriptional repressor and a zinc finger protein, also a master
regulator of EMT, which binds to subsets of E-box sites which appear to be different
than those for Twist: the specificity to differentiate between E-boxes is determined by
the central NN nucleotides (11) and partially by flanking sequences.

A classic,

canonical DNA binding site for Snail is located in the E-cadherin gene (E-cad) (11). The
role of Snail in metastasis, tumor progression, and endowing a stem-like phenotype as
part of its role in EMT and related processes has been well documented (7, 13, 14) and
has broad impacts on tumor growth and invasiveness (15). Snail contains four C2H2
zinc fingers, amino acids 156-176, 182-202, 210-230, and 238-255, as well as the SNAG
domain at amino acids 1-20 (Fig 1A).
In addition to these TFs, another TF which has been implicated in a wide range
of metastatic cancers is Sox9. Sox9 is a transcriptional regulator, which recognizes a
specific DNA sequence (GACAATG) and is part of the High Mobility Group (HMG) family
of proteins (16), and has been directly implicated in EMT during both development and
cancer progression (17, 18).

Twist has been shown to inhibit the transcriptional

regulatory functions of Sox9 (19), and it may impact the stabilization of Snail as well
(20). Sox9 is part of a subfamily of the Sox family of proteins (which is in itself a
subfamily of HMG proteins) which contains a dimerization (DIM) domain at amino acids
64-104 in addition to the HMG domain at amino acids 104-181 (Fig 1A). Recent studies

3

have also shown Sox9 to be critical in gating stage specific portions of metastasis, and
protecting tumor cells from the immune system (21)
This gives us a group of proteins, which all regulate similar functions, including
the ability for Twist and Snail to inhibit RunX protein function, which are potent drivers of
osteogenesis, which is an opposed cellular differentiation to chondrogenesis, of which
Sox9 is a critical regulator (22, 23) (Fig 1B). How these proteins function together to
regulate transcription of genes involved in EMT, given their various functions has been
unclear. We sought to use biochemical methods to dissect an endogenous complex to
clarify the manner of DNA binding and transcriptional regulation by these proteins.

Partial Epithelial Mesenchymal Transition and the EMTosome Hypothesis

It has become increasingly clear through recent research that partial EMT, also
called tumor budding, is critical to the process of metastasis in cancer (24). Full EMT
indicates a commitment to the mesenchymal phenotype, which bestows mobility and
resistance to stress, but also decreases the proliferative ability of these cells. While this
can be reversed by an opposite process, Mesenchymal Epithelial Transition (MET) (25),
to allow proliferation once the cancerous cells have reached a location to neocolonize,
that process, that seems to be less common in cells which have fully adopted the fully
mesenchymal phenotype than a partial state (24-26).

The specific molecular

mechanisms by which this can occur are unclear, and our research into the interactions
between these proteins should elucidate possible mechanisms for this process as well,
paving the way for future research in this direction.

4

Because of this, the hypothesis of this study is that there is likely a multiprotein
complex, capable of internally regulating itself based upon several factors. Transcription
factors typically form large, multiprotein complexes, but as of yet, only a tetramer of
Twist and E47 has been discovered.

In addition, the published model of binding

displays a platform of the WR domains of Twist in this tetramer, which would provide a
easily accessible binding surface for other proteins. This interaction with other proteins
in this way could modulate regulation of transcription through allosteric means. This
complex may only contain some of these proteins, or even only some of them at a time.
The binding of disparate proteins to the WR domain of Twist in this manner could
provide a novel mechanism of regulating the transcription of EMT genes. This would
provide a mechanistic basis for the partial EMT phenotype seen in metastatic cancer.
The goal is to discover members of this complex, identify their interaction domains, and
determine the molecular mechanisms by which they regulate the functions of the other
proteins in the complex.

As this complex contains many key EMT TFs in a single

complex, we have dubbed it the “EMTosome”.

5

Figure 1. The EMTosome complex contains Twist, E47, Snail, and Sox9, which all
regulate similar, yet different biological processes. A) Diagrams of full-length Twist,
E47, Snai1 (Snail), and Sox9. B) Diagram of some of the processes being regulated by
the members of the EMTosome protein complex, highlighting the many similar and
related processes regulated by different members of this complex.
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Chapter 2: Identifying Members of the EMTosome
Defining the domain architecture of full-length proteins, recombinant constructs
utilized, and DNA binding sites.

Dissection of the molecular mechanisms of this complex requires large amounts
of pure proteins for that purpose. This is best suited to bacterial expression systems,
however, all the proteins involved are unstable or toxic in E.

coli, so alternative

recombinant constructs had to be used, including codon optimization in some cases.
Twist and E47 exhibit similar issues to each other for this purpose, due to being binding
partners in the same superfamily of proteins, bHLH proteins. Codons were optimized for
E. coli for these two proteins. Both are bHLH proteins and are thus natively unfolded
unless interacting with each other. Primers for cloning were designed to maintain the
helix capping regions of each bHLH domain, as well as constructs both with and without
the WR domain in Twist (Fig 2A). In addition, since each requires binding partners to be
stable, they were cloned together into a dual expression plasmid (pETDuet) for coexpression in bacteria (Rosetta2 DE3 pLysS), suitable for the rare codons they possess
even after optimization. Following that, they were co-purified utilizing a 6xHis tag on the
N terminal of the recombinant Twist construct utilizing cobalt beads in native conditions,
and then purified by size exclusion chromatography (Fig 2B).

Peak fractions were

pooled and utilized for further studies. Elution from the column occurs at 44kDa and
larger according to the standard, and each individual protein is 13kDa (Twist/bHLH+WR)
and 9kDa (E47/bHLH).

This suggests either an extended, non-globular tertiary

structure, or tetramer formation.
7

For expression of recombinant Snail, we utilized the zinc finger regions, removing
the N-terminal region, and purified by 6xHis tag and Nickel-NTA beads under denaturing
conditions.

After purifying, we then refolded the protein by dialysis at high zinc

concentration in order to ensure the zinc fingers were properly refolded. Coomassie
staining at that point showed suitable concentration and purity for further experiments
(Fig 2C).

Recombinant Sox9 was cloned to remove the transcriptional regulation

domains at the C-terminus, PQA and PQS, and the recombinant construct was
comprised primarily of the dimerization and HMG domains (Fig 2B). Similarly to Snail,
Sox9 was purified under denaturing conditions utilizing a 6xHis tag and Nickel-NTA
beads, and refolded via dialysis, giving a protein of suitable concentration and purity for
further experiments (Fig 2C).
The A2M transcriptional regulation binding site for Twist consists of a dyad E-box
separated by five nucleotides. This has already been shown to be a highly responsive
transcriptional binding site for Twist (12), and for our research we utilized mutants,
where the E-box nucleotides have been scrambled as single mutants to one E-box or
the other, or as double mutants (Fig 1D). The canonical Snail DNA binding site, for Ecad, is also an E-box, but a single site non-dyad, and the central NN nucleotides provide
binding specificity for the different TFs, which bind E-boxes (11).

The Sox9 dimer

binding site has been shown to have high affinity for Sox9 (16), but the recognition
sequence has little in common with the A2M or E-cad TF binding sites.

8

Identification of complex members on dyad E-box DNA

To begin to assess the protein-DNA complexes associated with Twist, we
performed electrophoretic mobility shift assays (EMSA) using a canonical Twist dyad
binding site from the A2M promoter, using nuclear extracts from the breast carcinoma
cell line Sum1315, which is well-characterized for studying EMT (27). This cell line is
highly metastatic in xenografts(27), and displays markers for a stem-like, mesenchymal
phenotype in a large percentage of cells(28). This cell line has been used in other
studies specifically aimed at EMT transcription factors, and has been shown to be an
effective cell line for doing so(29). Additionally, we supplemented these analyses using
purified proteins for Twist, Snail, E47 and Sox9 and derivatives, as well as their
consensus DNA binding sites, as detailed previously.

Whole cell lysates and nuclear

extracts from Sum1315 cells were confirmed to contain Twist, E47, Snail, and Sox9, as
well as the other EMT markers, Slug and Vimentin (Fig 3A). We utilized EMSA with

32

P

radiolabeled A2M DNA probe and antibodies (Fig 3B) to verify the existence of a
complex and verify the presence of these proteins in that complex (Fig 3B). Nuclear
extracts from Sum1315 cells produced a consistent and reproducible complex with the
A2M DNA probe (lane 2). This primary complex shows altered mobility when Twist
antibody is added (Fig 3B, Lane 3), verifying the presence of Twist protein within this
complex as expected.

Surprisingly, the integrity of this primary complex is greatly

reduced by addition of Snail or Sox9 antibodies (Fig 3C) suggesting that both Snail and
Sox9 are additional binding partners in this multiprotein complex. (Fig 3B, lanes 4 and
5). When Twist antibody is added to the EMSA, we observe two higher mobility
subcomplexes form (Fig 3B, Lane 3). These two subcomplexes are in turn responsive to
both Snail and Sox9 antibodies (Fig 3B, Lanes 6 and 7). This suggests that the addition
9

of the Twist antibody, which is polyclonal to the full-length protein, partially breaks up this
complex, into smaller subcomplexes, which still bind to A2M DNA on their own. Once
again, for clarity, we denote this protein-DNA complex the “EMTosome”.

10
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Figure 2.

Recombinant constructs used are of suitable purity and stability,

showing clean, well separated proteins, and canonical binding sites for
EMTosome proteins highlighting where mutations were made to further illuminate
binding mechanisms. A) Diagrams of recombinant constructs used for these proteins.
B) SDS-PAGE of fractions from Size Exclusion Chromatography after native coexpression and copurification of Twist/bHLH+WR and E47/bHLH from cobalt beads with
both coomassie staining and Western Blot. C) Denaturing purification of His-Snail/ZF1-4
and His-Sox9/DIM+HMG utilizing nickel-NTA beads and then SDS-PAGE with
coomassie staining. D) Diagrams of oligonucleotides used in our study, showing the
double E-box of the A2M oligo, the mutations used to eliminate E-box specificity of
binding, the single E-box of E-cad binding site, and the consensus DNA binding site of a
Sox9 dimer.

12

Figure 3. The EMTosome can be easily detected in Sum1315 nuclear extracts,
which show markers for the EMT phenotype, and is responsive to antibodies for
Twist, Snail, and Sox9, showing that they for a complex on the A2M dyad E-box
recognition site. A) Sum1315 metastatic breast cancer cells show markers for the
EMT phenotype, as shown by Western blots of both whole cell lysate and nuclear extract
from Sum1315 cells.

B)

Electrophoresis Motility Shift Assay (EMSA) utilizing
13

radiolabeled A2M DNA probe utilizing antibodies to create motility shifts, showing the
responsiveness of the EMTosome to antibodies to Twist, Snail, and Sox9. DNA probe is
at 100nM concentration.
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Chapter 3: Dissection of the EMTosome; Assembly and Interactions

Protein-Protein interactions (PPIs) between complex members

Using these highly pure proteins we tested the ability of Snail to bind to Twist and
Sox9. Utilizing a GST-Snail-ZF1-4 fusion protein supplemented with nuclear extracts
from Sum1315 cells, we detected associations between Snail-ZF1-4 and both Twist and
Sox9, reproducibly and under harsh washing conditions (Fig 4A). The GST-Twist-WR
domain showed association with Twist and Snail from lysates, suggesting that the WR
domain of Twist is an interaction point with endogenous Twist and Snail (Fig 4A right
panel). Since these interactions are observed in cellular extracts and lysates, rather
than purified proteins, it does not indicate direct interactions, but is more indicative of
complex formation.
For direct interactions, however, a GST-Sox9/DIM+HMG fusion protein was also
able to associate with Snail/ZF1-4 recombinant protein under stringent wash conditions,
providing evidence that the interaction between Snail and Sox9 is likely direct (Fig 4B).
We also utilized transfected, Flag epitope tagged Snail, purified by anti-Flag
antibodies, to show that it was able to stably and directly bind to the Twist WR domain
when facilitated by the addition of the DNA binding site for Snail from the E-cad promoter
(Fig. 4C). Interestingly, Snail was unable to purify utilizing the Flag tag without the
addition of the E-cad promoter binding site.

Because the binding of the anti-Flag

antibodies to the Flag epitope tag should not be impacted by the stability of the protein,
as long as it is soluble, as it is in the nuclear extract as shown, this indicates that the
DNA binding of Snail induces an allosteric change throughout the protein, capable of
15

influencing antibody recognition and binding to the epitope tag. Together, these data
suggest that DNA binding by Snail derived from E. coli may help Snail fold into a
confirmation suitable bind to the Twist WR domain through some sort of allosteric
mechanism. These data support a direct association between Snail and Sox9, as well as
Snail and Twist. Furthermore, the interaction sites between these proteins are the WR
domain of Twist, the Zinc Fingers of Snail, and the dimerization and HMG domains of
Sox9. Thus, further supporting our observations of the EMTosome in SUM1315 cells.

Competition of DNA binding on dyad E-box DNA by other DNA binding sites

To further characterize the DNA binding properties of the EMTosome, we
analyzed the effects of competitor DNA (Fig 5A) on the endogenous complex in
Sum1315 nuclear extracts using EMSA utilizing order of addition experiments.

We

mixed radiolabeled A2M DNA binding site and an unlabeled probe (A2M, E-cad or Sox9)
at a 20x concentration prior to introduction of nuclear extracts and we observed that
binding of the Sum1315 EMTosome is eliminated by any of these three sites (Fig 5A,
Lane 3) when both hot and cold probes are mixed prior to protein addition. Alternatively,
when the EMTosome is first bound to radiolabeled A2M DNA, even the homologous
probe cold A2M was no longer capable of eliminating binding (Fig 5A, Lane 6),
suggesting a low rate of dissociation of the complex once bound to DNA. Cold probes
for E-cad and Sox9 binding sites, when added after EMTosome formation, also had
modest ability to diminish complex formation (Fig 5A lanes 7 and 8). The larger impact
on binding observed by the E-cad and Sox9 probes when compared to the homologous
probe suggests a mechanism of regulation where the DNA binding functions of Snail and
16

Sox9 are able to regulate the DNA binding of Twist and E47 to some degree.
Combined with previous data, this points towards an allosteric mechanism of regulation
throughout the complex, which is gated by the DNA occupancy of the other EMTosome
proteins.

Chromatin Immunoprecipitation (ChIP) of EMTosome proteins on canonical E-box
DNA binding sites

To

confirm

and

extend

these

findings,

we

performed

chromatin

immunoprecipitation in cells transfected with the core EMTosome components Twist,
Snail, E47 and Sox9.

We found that antibodies to Twist, Snail and Sox9 were all

capable of immunoprecipitating a Twist canonical binding target, the dyad E-box site on
the promoter region of the A2M gene, and a canonical Snail target, the single E-box site
in the promoter region of the E-cadherin gene (Fig 5B). These data support the ability of
these three proteins to occupy the appropriate sites in a cellular environment.

Specificity of individual proteins in DNA binding recognition

We next used purified recombinant proteins to determine the specificity of each
protein for recognition of its canonical DNA binding site and for cross recognition
amongst the EMTosome components. This detailed titration analysis revealed that each
protein (or protein complex in the case of Twist and E47) showed strong specificity for
their own canonical site but did not bind to sites recognized by the other components.
(Fig. 5C). Of most importance, Snail showed very little (100-fold less) apparent affinity
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for the dyad A2M E-box twist sites. Similarly, the Twist-E47 complex bound very poorly
to the canonical Snail site from E-Cad.
Neither Snail nor Twist-E47 proteins bound appreciably to the Sox9 site whereas
Sox9 bound it robustly. Thus, the observation (Fig 5A) that E-cad and Sox9 sites can
abolish binding of the EMTosome when bound to the dyad E-box cannot likely be
accounted for by competition at the level of DNA binding specificity overlap amongst the
probes. An alternative explanation is that Snail and Sox9 bind to Twist-E47 via proteinprotein interactions only, and that occupancy of Snail and Sox9 with their canonical sites
alters these protein-protein interactions with the Twist WR domain, thereby altering the
stability of the Twist/E47 tetramer formation on dyad E-box DNA.

Addition of recombinant Snail and Sox9 contribute to stability of Twist tetramer
formation on a dyad E-box

We tested if addition of recombinant Snail and Sox9 contribute to stability of
Twist tetramer formation on a dyad E-box by adding recombinant Snail and Sox9 to a
complex of purified Twist-E47 bound to the dyad site. We observed the more slowly
migrating band, previously documented as a tetramer formation of Twist and E47,
increase in abundance (Fig 6A, Lanes 3 and 4 compared to 10 and 11). Notably,
removal of the WR domain of Twist eliminated the ability of this higher order complex to
form, which could be partially recovered through addition of Snail and Sox9 (Fig 6B).
These data suggest that Snail and Sox9, while unable to bind directly to the A2M dyad
site, can still influence Twist-E47 binding to the site.
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Figure 4. All members of the EMTosome protein complex interact with each other
through direct or indirect interactions in a variety of conditions. A) GST-Snail/ZF119

4 affinity chromatography from Sum1315 nuclear extracts and GST-WR affinity
chromatography from Sum1315 cell lysates with both coomassie staining and Western
Blot shows that the Snail ZF region is capable of binding with Twist and Sox9 and the
Twist WR domain is capable of binding with Twist and Snail. B) GST-Sox9 affinity
chromatography with recombinant purified Snail/ZF1-4 with coomassie staining shows
that interaction between Sox9 and Snail is direct. C) Western Blot of flag epitope
purification of Snail-C-Flag from transfected Cos-1 nuclear extracts and then GST-WR
affinity chromatography shows that the interaction between Twist and Snail is direct with
the Twist WR domain.
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Figure 5. EMTosome binding to the A2M DNA target can be disrupted by the DNA
targets of any of the members, but once the EMTosome is bound to the A2M DNA,
it is largely refractory to cold competition. DNA probe is at 100nM concentration in all
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gels. A) EMSA with radiolabeled A2M DNA probe with Sum1315 Nuclear Extract and
competition with A2M, E-cad, and Sox9 unlabeled probes, both in equilibrium of hot and
cold probes, and binding of extract to radiolabeled probe first. B) ChIP from Quadruple
transfected Cos-1 Cells showing cohabitation of EMTosome proteins on A2M and E-cad
transcriptional binding regions. C) EMSA of Twist/bHLH+WR, Snail/ZF1-4, and
Sox9/DIM+HMG recombinant proteins titrated against A2M, E-cad, and Sox9
radiolabeled probes shows high specificity for each protein for their own consensus DNA
sequences.
800µM.

Twist/bHLH+WR + E47/bHLH complex concentration is from 3µM to

Snail/ZF1-4 concentration is from to 5µM to 1.25mM.

concentration is from 3.75µM to 1mM.
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Sox9/DIM+HMG

Figure 6. Snail and Sox9 stabilize Twist tetramer formation on a dyad E-box DNA
site. DNA concentration is 100nM in all gels. A) EMSA with radiolabeled A2M DNA
probe and titration of recombinant Twist/bHLH+WR /E47 complex with and without
Snail/ZF1-4 and Sox9/DIM+HMG recombinant proteins shows increased binding of
higher order complex in presence of Snail and Sox9. Concentration of Twist/bHLH+WR
/E47/bHLH complex is from 12.5µM to 100µM.

Snail/ZF1-4 is at 1.25mM and

Sox9/DIM+HMG is at 1mM. B) EMSA with radiolabeled A2M DNA probe with
recombinant Twist/bHLH+WR and E47/bHLH compared to Twist/bHLHΔWR and
E47/bHLH with and without recombinant Snail/ZF1-4 and Sox9/DIM+HMG shows that
the presence of Snail and Sox9 are capable of partially restoring the higher order binding
which is lost by removal of the Twist WR domain. Twist/bHLH+WR /E47/bHLH and
Twist/bHLHΔWR /E47/bHLH complexes are at 50µM (lanes 2 and 4) and 100µM (lanes
3 and 5) concentrations. Snail/ZF1-4 is at 1.25mM and Sox9/DIM+HMG is at 1mM.
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Chapter 4: Functional Reconstitution of the EMTosome
DNA binding contributes to stability of Snail and Sox9 in an allosteric manner

As further evidence of the influence of DNA binding on the folding/conformations
of Snail and Sox9, we revisited this for specificity, sparked by the data in Fig 4C that
Snail purification from transfected Cos-1 cells is greatly aided by the addition of the Snail
E-cad binding site (Fig 4C). We found that this effect is specific for the Snail E-cad DNA
binding site, as it was not observed using DNA oligos for the A2M dyad site or the SZF
zinc finger protein consensus binding site (a site unrelated to the E-box) (Fig 7A). A
similar effect of DNA binding is also evident upon Sox9 purification (Fig 7B). Thus, the
observed increase in protein purification is highly specific to binding their respective
binding sites. Since they are also fully soluble prior to purification, as the input lanes are
of nuclear extracts, this effect cannot be attributed to stability and solubility. These data
further support that there is some sort of allosteric mechanism triggered by the DNA
recognition of these proteins, which can influence the epitope recognition of α-flag
antibodies.

Assembly of EMTosome on dyad E-box DNA from endogenous and transfected
nuclear extracts.

We next analyzed the impact of each E-box DNA site contained in the dyad
target on the ability of the EMTosome to form using SUM1315 nuclear extracts. Utilizing
biotinylated A2M DNA binding sites, we observed that Twist, Snail, and Sox are all
capable of detection in protein complexes purified utilizing affinity chromatography with
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the dyad E-box probe (Fig 7C, left panel). We also observed that the dyad E-box is
required, since mutating either of the E-box binding sites abolished the ability of Twist,
Snail and Sox9 to be copurified in this manner (Fig 7C, left panel).
Utilizing the quadruple transfected nuclear extracts from Cos-1 cells rather than
the endogenous complex from Sum1315 cells, we still observed robust binding of Twist,
Snail, and Sox9 to the dyad E-box DNA binding site (Fig 7C, right panel). And while the
effect is lessened when compared to the endogenous complex, we still observed that the
ability for these proteins to copurify utilizing the dyad A2M DNA binding site is abrogated
by mutation of either E-box in the binding site (Fig 7C, right panel).

Transfections of EMTosome proteins into Cos-1 cells shows differential binding of
complex members

To analyze the reconstructed EMTosome, we performed a series of triple and
quadruple transfections into Cos-1 cells. With a triple transfection of Flag-Twist, HASnail, and Myc-E47, we observed that Twist and E47 copurify with α-Flag or α-Myc resin
(Fig. 8A). We also observed that Snail is capable of copurifying with Twist when FlagTwist, HA-Snail, and Myc-E47 are triple transfected into cells, but that this copurification
is eliminated on addition of the A2M DNA oligo, suggesting that complex formation may
require both Sox9 and DNA binding for stability. (Fig 8A). When a similar copurification
is performed with Cos-1 cell extracts containing transfected HA-Twist, Myc-E47, Sox9-CFlag, and Snail-C-Flag proteins, we observed that Twist and E47 are capable of
copurifying on a Myc-tag antibody resin (E47). Curiously, under the same conditions
HA-Twist is very poorly recovered with HA resin, and no recovery of Snail or Sox9 is
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seen (Fig 8B). These data, when combined with the previous observations made via
affinity chromatography, support the possibility that the DNA binding of this complex is
an integral part of complex formation, as attempts to purify the complex by other
methods than by affinity chromatography with the A2M dyad E-box site were not
successful.

Transfected Cos-1 cells shows similar behavior and motility as endogenous
EMTosome complex

To further characterize whether the EMTosome reconstituted in transfected cells,
EMSAs with antibody shifts were done with nuclear extract proteins from triple and
quadruple transfected cells (Fig 8C). By EMSA, the major complex co-migrates with the
endogenous complex, as observed many times from SUM1315 cells. A marked supershift of this complex is evident when Twist and E47 antibodies are added, but
surprisingly there is no effect of Sox9 antibodies in the quadruple transfection. There is
a modest but reproducible increase in the abundance of the major complex with the
addition of Sox9 to the transfections (Fig 8C, Lane 2 compared to Lane 6), while the
mobility of the complex remains overall similar to that of the SUM1315 (Fig 8C, Lane
10). Addition of cold competitor A2M and E-cad DNA (cold and hot DNAs mixed prior to
protein addition) showed that they robustly abrogate binding of the complex to the A2M
DNA binding site. However, addition of unlabeled Sox9 DNA binding site had a greatly
reduced impact on the binding of the complex to the A2M DNA binding site (Fig 5D,
Lanes 3-5).

Altogether, these data suggest that we only partially recapitulate the

components and activities of the EMTosome in transfected cells. It is also likely that
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additional undefined components and/or post translational modifications are present
endogenously in SUM1315 cells which are lacking in transfected Cos-1 cells.
All together, these data suggest that, while we can recover this complex utilizing
a DNA binding site of one element of the complex (Fig 7C, Fig 8C+D), the complex
cannot be fully recovered in the absence of DNA binding (Fig 8B), suggesting that the
DNA binding process is not separable from complex formation. In addition, the data
indicate that we can utilize the A2M dyad DNA binding site to capture Twist, Snail, and
Sox9 proteins from Cos-1 nuclear extracts transfected with Twist, E47, Snail, and Sox9
in a similar manner as with the endogenous complex from metastatic cancer cells (Fig
7C).
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Figure 7. Epitope tags on both Snail and Sox9 proteins from transfected Cos-1
nuclear extracts are stabilized by the addition of DNA recognition sites for each
respective protein, showing an allosteric change which is gated by DNA
recognition.

In

addition,

the

EMTosome

can

be

purified

by

affinity

chromatography from both endogenous nuclear extract from metastatic cancer
cells as well as by transfection into other mammalian cells. A) IP(Flag)-Western of
transfected Snail-C-Flag from nuclear extracts of Cos-1 cells, with and without addition
of E-cad DNA binding site and controls shows that Snail is greatly stabilized in presence
of its consensus DNA sequence. B) IP(Flag)-Western of transfected Sox9-C-Flag from
nuclear extracts of Cos-1 cells, with and without addition of Sox9 dimer DNA binding site
DNA binding and controls shows that Sox9 is greatly stabilized in presence of its
consensus DNA sequence

C) Western Blot of affinity chromatography from both

endogenous (Sum1315) and transfected (Cos-1; Twist, E47, Snail, and Sox9
transfected) nuclear extracts using biotinylated DNA probes of the A2M WT binding site
and mutants shows that the dyad E-box has much greater affinity for the EMTosome
complex than either individual E-boxes.
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Figure 8.

EMTosome can be partially reconstructed with triple and quadruple

transfections into COS-1 cells, as shown by Western blot and EMSA antibody
shift. A) IP-Western of nuclear extracts from triple transfection of Flag-Twist, HA-Snail,
and Myc-E47 into Cos-1 cells shows some interactions between Twist and Snail, and
this interaction can be modulated with the Twist dyad E-box DNA. B) IP-Western of
nuclear extracts from quadruple transfection of HA-Twist, Myc-E47, Sox9-C-Flag, and
Snail-C-Flag into Cos-1 cells show no interactions between Twist/E47 and Snail or Sox9
under these conditions. C) EMSA with radiolabeled A2M DNA probe using antibodies
to shift the motility of Cos-1 triple and quadruple transfected nuclear extracts show
responsiveness of the complex to Twist and E47 antibodies.
concentration.

D)

DNA is at 100nM

EMSA with radiolabeled A2M DNA probe using unlabeled DNA

competitors A2M, E-cad, and Sox9 dimer as competitors to binding of Cos-1 quadruple
transfected nuclear extract shows major inhibition of binding with both A2M and E-cad
DNA probes, and slight inhibition of binding with Sox9 consensus DNA. Radiolabeled
DNA is at 100nM concentration.
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Chapter 5: Molecular Mechanisms of Regulation of the EMTosome

Standard complex formation on dyad E-box DNA

Overall, our data support a working model for TFs implicated in EMT, which
incorporates important roles for Snail and Sox9 as regulatory components of a large
multi-protein complex on an EMT target gene, but which do not see the target gene
directly.

(Fig 9). When activating Twist DNA targets, Twist binds to a dyad E-box,

along with the rest of the EMTosome, where it regulates the transcription of the
associated gene (Fig 9A). This is generally regarded as the beginning of EMT, as it
results in Twist activating many of the genes typically associated with the mesenchymal
phenotype, such as A2M, BMP4, FILIP1L, SERPINF1, CSF2, NTSR1, SYT12, LAMB1,
and others (12).
Allosteric regulation by Snail and Sox9 dependent upon DNA recognition

When Snail or SOX9 bind to their DNA consensus sequences, recruiting the
EMTosome to those sequences, they restrict the transcriptional regulation of Twist by
eliminating the DNA binding capabilities in an allosteric manner (Fig 9, B and C). We
suspect that the WR domain is only properly available for binding to Snail and Sox9
when Twist-E47 tetramer is bound to its dyad site. In this scenario, a DNA bound WRdomain is a signal that Twist target genes are “on” and possibly, by tying up Snail in the
EMTosome, this keeps direct Snail targets off or not yet regulated.

The ability of Snail

in the EMTosome to engage its high affinity site, leading to instability or abolishment of
Twist-E47 binding to its target dyad site is then a toggle key switch between Twist
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regulated target genes and Snail or Sox9 regulated target genes.

This would further

differentiate Twist-E47 target genes from direct Snail target genes more so than just the
differences in the nucleotide sequence of the E-boxes do in the E-cads site and the dyad
sites. The dyad symmetric E-box clearly does this itself as 70% of sites obtained in our
initial Chip-seq experiments (12) were dyad symmetric sites with a 5-base spacing.
Moreover, most of these dyad E-box sites show little if any affinity for Snail.

It is an

interesting mechanism by which sequentially regulated target genes in a genetic
program are regulated by apparent allosteric regulation of DNA binding domains of
proteins present in the same macromolecular complex. It is also noteworthy that Twist is
largely defined as an activator of transcription whereas Snail is largely a repressor: this
further supports both a physical and functional separation of regulatory sub-programs in
the EMT phenotype. In addition, Sox9 has been implicated as more critical to later stage
tumor progression and immune evasion mechanisms at that point, showing further
support of a multistage, transitional phenotype where EMT TFs must activate in
sequence, at key points, for metastasis and tumor progression to occur (22, 23).
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Figure 9. Model of the Molecular Mechanisms of the EMTosome. A) Twist/E47 bind
to dyad E-box target DNA, and form the EMTosome complex on this DNA, resulting in
transcriptional regulation of Twist target genes. B) Snail binds to single E-box target
DNA, and forms the EMTosome on that target DNA, but by doing so allosterically
eliminates the ability for Twist/E47 to bind to their target DNA, preventing transcriptional
regulation by those factors. C) Sox9 binds to target DNA, and forms the EMTosome on
that target DNA, but like Snail, eliminates the ability for Twist/E47 to bind to their target
DNA, preventing transcriptional regulation by those factors.
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Chapter 6: Discussion and Conclusions

Discussion

We have targeted transcription factors specifically but taken an otherwise
unbiased biochemical approach to characterizing the components of this multiprotein
complex of Twist, E47, Snail, and Sox9 for determining the mechanisms of regulation of
this complex. These proteins have a robust presence in Sum1315 breast cancer cells,
which are highly metastatic and display a strong constitutive EMT phenotype, which has
been retained after metastasis(27-29). Utilization of the A2M DNA binding site in our
research was determined by responsiveness to the removal of the Twist WR domain,
which is indicative of tetramer formation, a necessary part of Twist regulated EMT(25).
We recognize that this limits the findings of this study to this specific DNA binding site
and thereby transcriptional regulation of a single gene. However, due to the similarities
of the DNA binding locations in other genes regulated by Twist, that of the double E-box,
we believe that the main findings can be extrapolated to other genes regulated by Twist
for EMT, but this extrapolation has not been validated as of yet.
Our main findings can be summarized as follows: 1) Twist protein derived from
highly metastatic SUM1315 cells is present in a multiprotein complex, which recognizes
the dyad E-box with high affinity. 2) This protein complex also contains Snail and Sox9,
placing three key TFs for the regulation of EMT into a single complex and this tripartite
EMTosome. Moreover, this complex can be reconstituted from cellular proteins derived
from transfected cells utilizing the dyad E-box as a ligand. Mutation of one E-box of the
dyad Twist A2M DNA binding site greatly reduces the ability to bind the endogenous
36

SUM1315 complex, showing high specificity for key DNA binding sites for formation of
the holo-complex.

3)

When the EMTosome from SUM1315 is challenged by

competition with the Snail E-cad DNA binding site or the Sox9 DNA binding site, the
ability for the complex to bind to the Twist A2M binding site is eliminated. This suggests
a mechanism for the regulation of Twist-E47 DNA binding based upon the occupancy of
DNA binding sites on the Snail and Sox9 proteins in the complex. Once bound to A2M
DNA binding site, the EMTosome shows very low dissociation from that site, while Snail
and Sox9 DNA targets are capable of still reducing binding, suggesting again a DNA
binding based allosteric mechanism for regulation. 4) Individual components of the
EMTosome are unstable/poorly folded in the absence of cognate DNA binding showing
that formation/folding is facilitated by DNA. Moreover, once formed the Snail and Sox9
components, which do not bind the Twist dyad site directly can still engage their own
cognate sites and regulate the overall binding activity of the complex.
In previous studies, the interactions and regulation between Twist and Sox9 for
chondrogenesis have already been categorized according to their genetic regulation of
each other, rather than by biochemical and molecular interactions (19). Most relevant
are the number of studies showing a strong genetic interaction between Twist, Snail and
Sox9 in a variety of forward and reverse genetically manipulatable systems in both
embryonic development and cancer models.

Our discoveries reported here greatly

complement and extend these by showing high affinity protein-protein interactions
amongst these proteins while also proposing a novel mode of their cross regulation.
Other studies showed a repressive effect of Twist on RunX proteins and
osteogenesis (30), a regulatory effect of Sox9 on Snail stabilization (20), and the impact
of downregulated Sox9 on many traits of metastatic cancer such as invasiveness,
proliferation, and the EMT phenotype (17). This provides a clearer picture of the large
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role that these TFs are playing in the chondrogenesis versus osteogenesis portion of
cellular differentiation, as well as maintenance of a stem-like phenotype. Combined with
the more EMT specific roles of these TFs (9), such as direct interactions of Twist with
Snail (31), we can see how these similar but distinct genetic processes can contribute to
metastatic spread, and understanding the mechanistic interactions between these
disparate TFs is crucial for designing targeted therapeutic approaches (32).
Recent research supports the premise that partial EMT, in which cells display
both epithelial and mesenchymal traits simultaneously, may be relevant to cancer
metastasis (24, 26, 33), suggesting that further research into the specific biochemical
mechanisms of this partial EMT phenotype are necessary. Our finding that several EMT
TFs are sequestered into a single complex, the EMTosome, and the occupancy of DNA
binding sites by one member impacts the DNA binding ability/affinity of the other
complex members, offers a mechanistic explanation for the partial EMT phenotype. Our
model proposes an efficient mechanism for controlling specific genetic differentiation
programs. By having different factors in a single multi-protein complex, different DNA
binding interfaces are available to be recruited at different target genes, allowing for
incomplete EMT phenotypes, such as loss of partial cellular junctions with added
motility, allowing cell clusters to metastasize rather than individual cells (24). In addition,
other mutations in this complex, such as the WR domain of Twist, have been shown to
contribute to other differentiation based pathologies, such as Saethre-Chotzen
Syndrome and Craniosyntosis (34, 35), where haploinsufficiency results in defects in the
differentiation of the neural crest (36-38). This once again ties these proteins into the
regulation of differentiation in another manner, showing that the implications of a single
multiprotein complex with these members could be responsible for regulation of a wide
range of differentiation based cellular processes.
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There are many possible biological implications of this mechanism. We know
that EMT is activated in a very specific, hierarchical sequence, starting with Twist
mediation of the transcriptional activation of many Mesenchymal target genes. This is
then followed by Snail repression of Epithelial target genes. By having this mechanism
by which the EMTosome selects one transcriptional regulatory program over another, it
is possible to control this sequence of activation and repression, thereby controlling the
signaling of these diverse regulatory pathways. This selection is likely due to epigenetic
regulation of DNA binding site availability, and recognition could be dependent upon
pioneer factors, histone modifications, or other forms of chromatin remodeling. This
mechanism can have broad impacts in not only controlling this sequential activation and
repression necessary for EMT, but also provide a mechanism by which mis regulation
can result in only a partial EMT phenotype.

This partial EMT phenotype has been

shown to be necessary for colonization of distal sites in the body after metastatic
migration, as it is then easier for the reverse process Mesenchymal-Epithelial Transition
(MET), to occur, which is necessary to restore the proliferation of these metastatic cells,
or even allowing that proliferative ability to remain during the EMT state. This also
opens an avenue of possible therapeutic impacts from this research.

EMT greatly

enhances therapeutic resistance in cancer, so inhibition of this complex could decrease
therapeutic resistance. EMT inhibition could also have broad impact as an adjuvant
treatment in concurrence with other cancer treatments such a chemotherapeutics,
possibly increasing their efficacy.
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Conclusion

In summary, multiple EMT TFs, Twist-E47, Snail, and Sox9, are sequestered into
a single multiprotein complex, we have designated the EMTosome. The DNA binding
activities of these TFs appears to cause allosteric changes which can result in increased
stability and modulate the DNA binding activities of other TFs in the complex. This
provides a mechanism for the hierarchal, sequential series of genetic regulatory
programs which must activate and deactivate in a precise way to drive EMT. DNA
binding of one protein and then sequestration of the other proteins in the EMTosome
away from other target DNA also provides a biochemical and molecular mechanism by
which partial EMT, a potent driver of cancer metastasis, can occur. In addition, these
finding can better inform future efforts to target the EMT process in cancer cells, which is
responsible not just for metastatic spread, but also therapeutic resistance in a broad
range of cancers.
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Chapter 7: Future Directions

Structure

As we have determined molecular mechanisms of regulation and complex
members, an obvious next step would be structural studies, to determine the precise
structure of the EMTosome. This could be accomplished a number of ways, the most
evident being crystallography or NMR. For crystallography, we already have optimized
the purification of Twist/E47 in complex together via both affinity chromatography and
size exclusion chromatography. Unlike most of the TF purifications reported here, Twist
was purified via native purification because Twist is highly unstable without a binding
partner, necessitating a native purification protocol. A number of optimization steps still
need to be done for buffer consistency and concentration of these proteins in order to
prepare them for attempts to setup crystal trays for crystallography. In specific, the
buffer used for size exclusion crystallography can be varied, and then centrifugal
concentration can be used to attempt to attain proper concentrations for crystallography.
After concentration, DLS can be utilized to assess monodispersion, aggregation, and
purity, to inform proper buffer composition with which to process for crystallization.
Another possible route for determination of structure can be NMR. As with the
crystallography suggestion, the Twist/E47 complex is already optimized for purification
through affinity chromatography and size exclusion chromatography. Isotopic labelling is
then necessary. Utilization of a minimal media with

15

NH4Cl and

13

C-glucose for double

labelling would be recommended as it is common, straightforward, and many
optimization strategies for this method are available as needed(39).
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These structural findings can also provide novel insights into identifying possible
interaction points not only between these proteins, but possibly others as well, just as
the published model of Twist/E47 binding informed us as to the nature of the WR domain
as a PPI platform.

Mapping of interaction domains
Determination of specific contact residues and the relevance to binding can help
inform future efforts at understanding, and perhaps inhibiting the molecular mechanisms
of the EMTosome. This can be done without structural information, as we have already
identified the interaction domains in this complex.

However, additional structural

information can help narrow down the possible contact surfaces and alleviate much of
the work involved in this process. For determining specific contact residues, a series of
site directed mutagenesis experiments could be done to perform “alanine scanning”
across these domains. The domains in question are the dimerization and HMG domains
of Sox9, the WR domain of Twist, and the Zinc Finger domains of Snail. By mutating
three residue sections to alanine in each of these domains, we can determine which
sections, when mutated, prevent the interactions between these specific proteins. The
first step after the mutagenesis would be to repeat the GST binding assays (Fig 4)
previously shown in this dissertation with these alanine scanning mutants, to see which
mutations abrogate the protein-protein interactions. After this has been determined, in
those three alanine sections from the scanning, we can do individual site directed
mutagenesis of each of the residues to alanine and follow that up with ITC experiments
to calculate the specific thermodynamic contributions of each interaction. SPR could be
utilized with the same constructs used for the previous GST binding assays (Fig 4).
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While the reagents and protocols for that should already be mostly optimized to alleviate
much of the difficulties in such an experiment, the solid phase nature of SPR
experiments make this a less than ideal aim when compared to ITC data. This data can
then be used to inform future investigations, such as the next proposed one, high
throughput screening of small molecule inhibitors.
High throughput screening of inhibitors

Another future direction for investigation of the EMTosome is screening of
inhibitors for complex formation and regulation.

By inhibiting the formation of this

complex, we can potentially reduce therapeutic resistance in metastatic cancer, thereby
improving the efficacy of existing treatments.

The determination of structure and

mapping of interaction domains previously proposed can greatly aid in this goal of
demonstrating biological impact through inhibition of this complex. Since these proteins
are expressed differentially in metastatic tissues (expect E47 which is expressed
ubiquitously), targeting this EMTosome complex for inhibition would add a degree of
specificity to treatments which would reduce toxicity and off target effects, a common
problem with cancer treatment. Targeting of these interactions and disrupting the ability
to recruit other EMTosome proteins into the complex could potentially destabilize
transcriptional regulation, reversing the process, and reducing the therapeutic
resistance, which EMT imparts. Our lab has previously proposed similar experiments for
grants, which would involve in silico investigation of complexes utilizing a selection of
over a million small molecules in simulations. This would require structural or model
data in order to inform that in silico process, and that would be an ideal route to start, but
in the absence of such, there are selections of libraries of small molecule inhibitors
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available for SPR testing in a high throughput manner which can be substituted for such.
As we have already utilized constructs suitable for SPR testing, with both GST and His
fusions, much of the preparatory work for this is already accomplished, and with minor
optimization, is ready for high throughput testing in this manner. Ideally, we would be
able to identify a selection of small molecule inhibitors via high throughput SPR, and
then validate these small molecules via ITC to determine the impact they have on the
aforementioned interactions.

The previously suggested alanine scanning can better

inform this portion of the experiment but is not critical to it. Ultimately, understanding
these molecular mechanisms, the structures, and functions of these interactions can
inform us for directions to develop potential inhibitors to the process of EMT in cancer.
Of note is the impact that EMT has on therapeutic resistance in cancer. By inhibiting this
process, and thereby removing therapeutic resistance, there is the potential to increase
the efficacy of other therapeutic treatments.
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Chapter 8: Allosteric Regulation of BAP1 by ASXL2

Introduction

In addition to my work with on the EMTosome project, through my thesis work I
have been heavily involved in another project on the allosteric regulation of BRCA1
Associated Protein 1 (BAP1) deubiquitinase (dUb) function (citation here of BAP1
paper). BAP1 is an ubiquitin hydrolase which is mediated by interactions with polycomb
group-like protein ASXL2. ASXL2 is an obligate partner for BAP1 enzymatic activity,
through binding with BAP1 UCH37-like domain (ULD) domain, which in turn binds to
BAP1 Ubiquitin C-terminal hydrolase (UCH) domain. Our goal was to determine the
molecular dynamics, kinetics, and stoichiometry of this interaction and regulation, and a
portion of that research is presented here to give a clear, yet concise, picture of the
workings of that mechanism.

As such, much of the following is from the currently

unpublished work “Kinetics characterization of ASXL1/2-mediated allosteric regulation of
BAP1 deubiquitinase” by Hongzhuang Peng, Joel Cassel, Daniel S. McCracken, Jeremy
W. Prokop, Paul R. Collop, Alexander Polo, Surbhi Joshi, Jacob P. Mandell, Kasirajan
Ayyanathan, David Hinds, S. Bruce Malkowicz, J. William Harbour, Anne M. Bowcock,
Joseph Salvino, Eileen J. Kennedy, Joseph R. Testa, and Frank J. Rauscher III, which is
currently under peer review.
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Background

BAP1 is an ubiquitin hydrolase which interacts with BRCA1 and enhances
BRCA1-mediated inhibition of breast cancer progression (40). At the N-terminus of
BAP1 is the UCH domain which cleaves ubiquitin from ubiquitin-conjugated small
substrates. BAP1 contains two protein-binding motifs for BRCA1-associated RING
domain protein 1 (BARD1) and Breast cancer type 1 susceptibility protein (BRCA1),
which form a tumor suppressing heterodimer complex (41), as well as a binding site for
Host cell factor 1 (HCF1), which interacts with a histone-modifying complex during cell
division (42). The C-terminus of BAP1 contains two nuclear localization signals and a
ULD domain which interacts with ASXL family members to form the polycomb group
(PcG)-repressive deubiquitinase complex. This PcG-dUb complex is involved in stem
cell pluripotency as well as other developmental processes (43, 44).
Analysis of the homology of the BAP1-UCH and other UCH-like proteins implies
a role for either ubiquitin-mediated, proteasome-dependent degradation or other
ubiquitin-mediated regulatory pathways in BRCA1 function, in cellular growth,
differentiation, and homeostatic processes (40, 45, 46). BAP1 exhibits oncosuppressor
activity in cancer cells (40, 41) and in vivo (47). Somatic mutations/deletions of BAP1 are
found in metastasizing uveal melanomas, malignant mesothelioma, and other cancers
(48-50). In addition, germline mutations of BAP1 were found in families with a high
incidence of mesothelioma, uveal melanoma, benign and malignant cutaneous
melanocytic tumors, basal cell carcinoma, meningioma, and renal carcinoma (50-54).
This condition is typically termed Tumor Predisposition Syndrome and understanding it
fully is critical to further research into this malignant pathology.
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Cancer-related mutations/deletions of BAP1 often result in loss-of-function by
causing premature protein termination, protein instability and/or loss of UCH catalytic
activity. Other mutations of BAP1 lead to loss-of-function by targeting the ULD domain,
thereby disrupting binding to ASXL2 (55) an obligate partner for BAP1 enzymatic
activity.
BAP1 interacts with a large polycomb-like complex through the ASXL1/2 family
members (44). The Drosophila PcG Calypso protein is homologous to BAP1. Calypso
interacts with PcG protein Asx, and this Polycomb repressive deubiquitinase (PR-DUB)
complex binds to PcG target genes. The human homologs of Asx are ASXL1-3 (55). The
N-terminus of ASXL contains the highly conserved Asx homology domain (ASXH), which
is required for Calypso/BAP1 protein binding. Similar to Drosophila Asx, human
ASXL1/2-BAP1 complexes deubiquitinate histone H2A. Mutations of ASXL1/2/3 genes
leading to protein truncations have been found associated with human cancers and
other diseases (56-59). One example is loss-of-function mutations in ASXL1, which
encodes an epigenetic modifier that plays a role in polycomb repressive complex
(PRC2)-mediated transcriptional repression in hematopoietic cells. Such loss-of-function
mutations in myeloid malignancies result in loss of PRC2-mediated gene repression of
leukemogenic target genes (56). The crystal structure of Drosophila PcG-dUb has
revealed that the deubiquinase Calypso and its activating partner ASX form a 2:2
complex. This structure has informed and verified previously published models of
BAP1/ASXL binding and interactions (55).

This bidentate Calypso ASX complex is

generated by dimerization of two activated Calypso proteins through their coiled-coil
regions.

Disrupting the Calypso dimer interface does not affect inherent catalytic

activity, but inhibits removal of H2AK119Ub as a consequence of impaired recruitment to
nucleosomes (60).
47

Previous studied have shown that the familial and somatic BAP1 mutations
inactivate ASXL1/2-mediated allosteric regulation of BAP1 deubiquitinase by targeting
multiple independent domains (55). The AB Box of ASXL2 mediates the binding of ULD
and UCH domains of BAP1 to form a tripartite complex, which subsequently stabilizes
the UCH structure, thereby increasing the catalytic activity of BAP1-UCH. The tumorderived discrete in-frame deletions and insertions outside of the BAP1 catalytic domain
(UCH) disrupt the BAP1-ASXL2 interaction, leading to tumor-related loss of BAP1
catalytic activity. This project examines the molecular dynamics of the interaction,
measures the kinetic and stoichiometric impact of mutations on proteins binding and on
the enzymatic activity of BAP1, and provides novel insights about the structural and
dynamic parameters of the BAP1-ASXL2 interaction.

Structure and domain architecture of BAP1/ASXL2

A model of the structure and interactions of BAP1 and ASXL2 show the binding
of these proteins to ubiquitinated H2A (Fig 10 A). This show the catalytic loop of BAP1UCH interacting directly between H2A and Ub to perform dUb activity. It is stabilized in
place by the BAP1-ULD domain, which in turn is stabilized by the ASXL2-AB domain.
This model serves as a structure-function basis for showing the regulation of the dUb
activity of BAP1 through these protein-protein interactions regulating BAP1 through
these allosteric mechanisms.
The constructs used in this study, along with the domain architecture of each
protein, are depicted (Fig 10 C). These proteins can be readily purified in a stable and
soluble manner with both bacterial and baculoviral expression systems, as either single
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proteins, or expressed in complex (Fig 10 D). For single protein expression, His- or
GST-tagged full-length BAP1, BAP1-UCH and BAP1-ULD domains were expressed in
bacteria (Bac-) or baculovirus (Bv-), respectively (Fig 10C). The reasons that we
expressed the proteins in baculovirus were in case post-translational modifications are
needed for the protein functions and/or that other cellular factors are involved in the
protein functions. All the baculovirus-expressed proteins and domains were soluble
using Ni2+-NTA chromatography under native purification conditions (Fig 10D) and the
proteins were functional (see below). The bacterial-expressed GST-BAP1-UCH and
GST-BAP1-ULD were soluble using GST-chromatography under native purification
conditions (Fig 10D) and the proteins were functional (see below). The bacterialexpressed His-BAP1-ULD and His-ASXL2-AB proteins were purified under denaturing
conditions, followed by a re-naturation protocol that yielded soluble, highly active
proteins (Fig 10D). However, the yield of re-folded proteins was not sufficient for
structural studies. We thus used the pETDuet co-expression system to co-express HisULD and AB, or His-AB and ULD protein complexes in E. coli [Rosetta 2 (DE3) pLysS].
The His-ULD/AB protein complex was successfully co-expressed and then purified using
cobalt beads (Talon) under native purification conditions. The protein complex was
highly soluble and functional (Fig 10D).
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Figure 10. BAP1 and ASXL2 structure, and domain architecture of human BAP1
and ASXL2 and the proteins/domains used in this study. A) Model of the BAP1-UCH
domain with colors as: Histone 2A (blue), ubiquitin (yellow), ULD (blue line), UCH loop
(cyan), ASXL2 (green); reveals additional BAP1 uniquely conserved amino acids for the
stabilization by ASXL2 depicted in green near the UCH loop. B) This is a zoomed in
view of ASXL2, ULD, and UCH interactions. C) Human BAP1 depicting ubiquitin Cterminal hydrolase domain (UCH; aa 1-240), BARD1 and BRCA1 binding domains,
NHNY consensus sequence for interaction with HCF1, UCH37-like domain (ULD: aa
598-729), and nuclear localization signals (NLS). Domain structure of human ASXL2
contains highly conserved AB box and PHD domain. D) BAP1 and ASXL2 proteins
produced in bacteria and baculovirus either singly or by co-expression. The proteins or
protein complex were purified using either Ni-NTA, cobalt beads (Talon) or GST-resin.
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The purified proteins and protein complex were analyzed by NuPAGE and visualized by
Coomassie staining. (Credit to Jeremy W. Prokop for A/B, Hongzhuang Peng for C/D)
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Biophysical and biochemical characterization of BAP1-UCH, BAP1-ULD, ASXL2AB, and the UCH/ULD/AB complex

To evaluate the behavior of singly expressed proteins and co-expressed protein
complex, DLS was used to examine the mono-dispersion of His-ULD, His-AB and HisULD/AB complex. We first tested a full spectrum of buffer conditions for optimizing the
solubility and stability of individual proteins and the protein complex. Under the optimal
buffer condition found (50 mM potassium phosphate, pH 7.5, 200 mM potassium
chloride and 1 mM TCEP), His-AB and His-ULD were mono-dispersed 87% and 88%,
respectively. Each scan shows a larger species as well, which is assumed to be protein
aggregation (Fig 11A).
When this ULD-AB complex forms together, the mono-dispersion is measured at
91.8%. This indicates a similar, or perhaps slightly higher stability of the complex than
the isolated proteins. In addition, we see a shift in the scan to a smaller size complex
when these protein domains are bound together. This is contrary to what would typically
be expected as proteins bind together. Based upon this result, it appears that the
complex is more tightly packed spatially than the individual proteins. In addition, these
data were utilized for further ITC experiments (Fig 11B) in calculating concentrations
used, because it is assumed only the mono-dispersed species is capable of interacting
properly with the other complex members.
From our previous studies (55), we learned that the BAP1-ULD domain interacts
directly with the ASXL2-AB box. However, the binding kinetics and stoichiometry of
interaction of the ULD domain and the AB box remained unknown. Using ITC, we have
now determined the thermodynamics, kinetics, and stoichiometry of this domain-domain
interaction. Highly purified His-ULD and His-AB proteins were critically equilibrated in the
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same buffer (50 mM potassium phosphate, pH 7.5, 200 mM potassium chloride and 1
mM TCEP). The His-AB was placed in the ITC cell with 77 µM protein concentration
while the titrated protein His-ULD was at 574 µM protein concentration. We also set the
references for each protein (see Materials & Methods) for subtraction from the
experimental data. The data show that K d for interaction of His-ULD and His-AB is
approximately 4.26 µM (3.73 µM-4.85 µM). The stoichiometry of His-ULD to His-AB is
1:1 molar ratio (Fig 11B). We also observed that the thermodynamics of the interaction
has a ΔH of -9.87 kcal/mol and ΔS of -10.3 cal/mol/deg, indicating an exothermic
interaction. These data are consistent with our previous studies that used computer
modeling technology to predict the molecular model of BAP1-ULD interacting with
ASXL2-AB (55). The interaction for both ULD and AB has a modest binding affinity
dissociation constant. This result is consistent with expectations of formation of a
protein-protein complex in a reversible manner.
Using computer molecular modeling of UCHL5 structures, we predicted that the
BAP1-ULD domain folds back to the BAP1-UCH catalytic domain and that the ASXL2AB box stabilizes the UCH catalytic loop via a unique BAP1 mechanism not seen in
other UCH proteins, allowing for ubiquitin to fit into the active site (Fig 10A/B). The GSTUCH directly interacted with the ULD domain but did not directly interact with the AB
box, while the ULD domain recruited the AB box so that they form a stable complex (55).
Now, we have co-expressed and co-purified the His-ULD/AB domain complex using the
pETDuet system, which allowed us to obtain well-folded protein complex (Fig 10D). To
test this highly purified protein complex, a GST association assay was performed. GST
or GST-UCH was pre-coated on the GST resin, followed by incubation with His-ULD/AB
complex. After washing with BB200 or BB500 buffer, the GST resin with protein complex
was extracted, analyzed by SDS-PAGE, followed by Coomassie staining. The result
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showed that the His-ULD/AB complex was pulled down by GST-UCH but not by GST
(Fig 10C). The UCH/ULD/AB protein complex was indeed formed.
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Figure 11. Biochemical and biophysical analyses of purified proteins and protein
complex from BAP1 and ASXL2. A) Dynamic light scattering (DLS) was used to
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examine the mono-dispersion of His-ULD, His-AB and His-ULD/AB complex. Under the
optimal buffer condition, His-ULD and His-AB proteins showed 88% and 87% monodispersion, while His-ULD/AB protein complex exhibited a higher degree (91.8%) of
mono-dispersion, as directly measured by DLS. B) Isothermal titration calorimetry (ITC)
was used to determine the thermodynamics and kinetics of domain-domain interactions
between His-ULD and His-AB and their stoichiometry. 574 µM His-ULD protein was
titrated into 77µM His-AB protein in terms of molar ratio. ITC calculations derived from
the direct measurements and curve fitting were done with Origin 7 software. The binding
affinity with dissociation constant of the protein-protein interaction and the stoichiometry
of protein complex were determined. C) Binding of co-purified His-ULD/AB and the
UCH domain of BAP1, as demonstrated by GST-UCH pull down with recombinant HisULD/AB complex.
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Stimulation of BAP1 deubiquitinase activity by ASXL2-AB and ULD/AB complexes

In order to measure BAP1 deubiquitinase activity, we used the fluorogenic
substrate Ubiquitin-AMC (Ub-AMC). The activity of the UCH domain of BAP1 was 5-fold
greater than the full-length BAP1, with specific activity values of 358 ± 6.6 pmol
AMC/min/pmol E and 73 ± 2.4 pmol AMC/min/pmol E, respectively (Fig. 4). For both
full-length BAP1 and the UCH domain, a point mutation of the cysteine residue at
position 91 completely abolished enzyme activity (Fig. 12A), consistent with previous
observations (55).
The ASXL-AB box stimulates BAP1 deubiquitinase activity in the Ub-AMC assay
(55). In this study, we further characterized this effect by testing increasing
concentrations of ASXL2-AB in the presence of a substrate titration of Ub-AMC. ASXL2AB dose-dependently increased the maximal velocity of BAP1 cleavage of Ub-AMC by
2.5-fold (Fig 12B). The Km values for Ub-AMC in the presence of increasing
concentrations of ASXL2-AB ranged from 4-9 mM and did not correlate with ASXL2-AB
concentration, suggesting that the ASXL2-AB box stimulates BAP1 enzyme activity by
increasing its Vmax, rather than the Km for Ub-AMC. In addition, from these data we were
able to obtain a functional potency for ASXL2-AB stimulation of BAP1 enzyme activity by
plotting the Vmax values for BAP1 enzyme activity against the concentration of ASXL2-AB
box (Fig 12C). These data fit well to a typical one-site dose response curve with a Hill
slope of 1.0 and an EC50 of 0.96 nM (95%CI: 0.42-2.4 nM) (Fig 12C).
We then determined the functional potency of the His-ULD/AB complex
expressed in the pET-Duet-1 co-expression vector. Since we established that ASXL2-AB
stimulates BAP1 deubiquitinase activity by increasing the Vmax, we simply measured the
specific activity of BAP1 in the presence of increasing concentrations of His-ULD/AB in
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order to conserve substrate (Fig 12D). The His-ULD/AB complex stimulated BAP1
specific activity 4.5-fold using 100 nM Ub-AMC (Fig 12D). Data plotting the specific
activity values against ULD/AB concentration fit well to a one-site dose response curve
with a Hill slope of 1.0 and an EC50 of 2.8 nM (95%CI: 1.0-7.5 nM) (Fig 12D), which is
within 3-fold of the functional potency we obtained for ASXL2-AB.
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Figure 12. Cleavage of Ubiquitin-AMC mediated by full-length wild-type BAP1,
full-length C91S BAP1 mutant, wild-type UCH domain of BAP1, or mutant C91S
UCH domain, and the effects of the ASXL2 AB Box on that cleavage. A) Enzymes
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were expressed in baculovirus with an N-terminal His-tag and purified using standard
procedures. A range of concentrations for each enzyme was incubated with 100 nM
Ubiquitin-AMC in 20 µL of 25 mM HEPES pH 7.4, 150 mM NaCl, 5 mM DTT and 0.005%
Tween20 in 384-well plates. Fluorescence of free AMC was excited at 355 nm and
emissions were measured at 460 nm at 2 min intervals. The resulting progress curves
were fit to a straight line, and the velocities were plotted against enzyme concentration to
obtain specific activities.

Data points are means of duplicate determinations from a

single experiment, which was repeated twice. B) Ubiquitin-AMC substrate titrations
were incubated with full-length BAP1 (3 nM) in the presence of increasing
concentrations of AB in assay buffer as described in Materials and Methods. The
resulting progress curves were fit to a straight line and the velocities plotted against
Ubiquitin-AMC concentration and the data fit to the Michaelis-Menton equation.

C)

Potency of AB-mediated stimulation of maximal velocity of BAP1. Each Vmax value
from panel B was plotted against AB concentration, and the data fit to one-site dose
response equation as described in Materials and Methods. D) Full-length BAP1 was
titrated in the presence of increasing concentrations of ULD/AB complex and 100 nM
Ubiquitin-AMC in assay buffer as described in Materials and Methods. The resulting
progress curves were fit to a straight line, and the velocities were plotted against enzyme
concentration to obtain specific activity. E) Potency of ULD/AB complex on specific
activity of BAP1. Slopes from panel C were plotted against ULD/AB concentration and
the data fit to one-site dose response equation as described in Materials and Methods.
Data points are means of duplicate determinations from a single experiment, which was
repeated twice. (Credit Hongzhuang Peng)
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Discussion

In this report, we have characterized protein-protein interactions between BAP1
and ASXL2 utilizing biochemical and biophysical approaches, as well as enzymatic
activity analyses. We have investigated the molecular dynamics, kinetics, and
stoichiometry of these intra-molecule and inter-molecule domain-domain interactions.
We draw the following conclusions. First, all of the single- or co-expressed and purified
recombinant BAP1 and ASXL2 domain/proteins or protein complexes from both bacteria
and baculovirus are well-folded in structure and are functionally active. Second, the
interaction between BAP1 and ASXL2 is direct, specific, and stable to in vitro
biochemical and biophysical manipulations. The association of the AB-box greatly
stimulates BAP1 deubiquitinase activity. Both bacterial- and baculoviral-expressed BAP1
or BAP1-UCH were enzymatically active, and the enzymatic activity increased greatly
upon ASXL2-AB box stimulation. A stable ternary complex is formed in UCH/ULD/AB
domains. Third, the binding affinity of the ULD domain of BAP to the AB box of ASXL2 is
moderately high and one molecule of the ULD domain directly interacts with one
molecule of the AB Box.
To further characterize interactions of domain-domain and tripartite complex
between intra-molecule and inter-molecules of BAP1 and ASXL2 proteins, we applied
biochemical and biophysical approaches. All these highly purified single- or coexpressed proteins are well structured and capable of folding properly, which allowed us
to study the dynamic kinetics of their interactions and stoichiometry of the protein
complex association by ITC (Fig 11B). More importantly, the high quality of the bacterialor baculoviral-expressed proteins and protein complexes are highly functional, which
enabled us to perform highly sensitive assays to evaluate deubiquitinase-specific activity
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of BAP1 and the direct effects of stimulation of ASXL2 on BAP1 enzymatic activity (Fig
12). These domain-domain interactions and ternary complex interactions were direct and
stable (Fig 11C) and do not require post-translational modifications. We not only were
able to reconstitute the tripartite domain complex in vitro, but also were able to study the
real-time dynamic kinetics of protein-protein interactions. Moreover, the stoichiometry of
AB and ULD association occurs via one molecule of AB binding to one molecule of ULD
with high affinity (Fig 11B), which is consistent with the crystal structure of Drosophila
Calypso / Asx. The stoichiometry of Calypso/Asx was 1:1 molar ratio in low protein
concentration, and 2:2 molar ratio in high protein concentration (60). Crystal structure
work on the deubiquitinase Calypso, the Drosophila counterpart of BAP1, and its
activating deubiquitinase adaptor (Deubad) protein partner ASX have provided a
structural basis to interpret studies demonstrating that the ASXL1/2 Deubad domains
bind tightly to BAP1, and thereby activate the PR-DUB complex by forming a composite
binding site for ubiquitin (60). As in our study, Foglizzo et al. (60) showed that mutations
at the juncture between DUB, Deubad, and ubiquitin have a deleterious effect on the
ability of the PR-DUB to interact with ubiquitin.
We previously showed that the AB box of ASXL2 is the minimal domain required
to interact with and stimulate the deubiquitinase activity of BAP1. Mutations in the AB
box of ASXL2 or in the ULD domain of BAP1 either partially or completely impacted AB
and ULD interaction and UCH ubiquitin hydrolase activity. In this study, we further
quantified the AB box protein stimulation on either full-length BAP1 or UCH domain
deubiquitinase activity. We observed that ASXL2-AB dose-dependently increased the
maximal velocity of BAP1 cleavage of Ub-AMC. Moreover, the ULD/AB complex also
increased the maximal velocity of BAP1 cleavage of Ub-AMC in a dose-dependent
manner. The data fit well into a one-site dose response equation. The AB box increases
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the maximal velocity of BAP1-mediated cleavage of Ub-AMC rather than increasing the
Km for this substrate. This is consistent with our molecular modeling data suggesting that
the AB box does not induce a conformational change in the substrate’s binding pocket,
but rather binds to the ULD domain and stabilizes the UCH loop of BAP1. The potency
of the AB box for stimulating BAP1 mediated cleavage of Ub-AMC is similar to the
concentration of BAP1 in the enzyme assay, which suggests a 1:1 interaction. This is
consistent with the ITC results reported here.
Interestingly, the ULD/AB complex, but not the AB box alone, was able to bind
the BAP1-UCH domain, as determined by SPR (data not shown), suggesting that
interaction with the ULD domain is essential for stabilizing the UCH domain of BAP1. As
the ULD is also found in UCHL5, this makes sense. In addition, most of the affinity for
the AB box for BAP1 is through the ULD domain, as this interaction had 10 to 20-fold
higher affinity compared to the affinity of the ULD/AB complex for the UCH domain (data
not shown). These data suggest that the AB box binds the ULD domain first, and this
complex then interacts with the BAP1-UCH domain to stimulate enzyme activity.
This is the first quantitative assessment of the inter- and intra-molecular
interactions of the BAP1 tumor suppressor and its obligate partner for enzymatic activity,
ASXL2, including the mode by which the ASXL2-AB box mediates BAP1 deubiquitinase
activity. The tripartite (UCH/ULD/AB) domain-domain interactions described here explain
the loss of the BAP1 deubiquitinase activity when tumor-associated mutations in BAP1
occur outside of the catalytic UCH domain, each failing to productively recruit the AB box
to the wild-type BAP1 catalytic site via the ULD, resulting in loss of BAP1 deubiquitinase
activity.
In summary, through an integrated use of molecular biology, biochemistry, and
biophysics strategies, we have provided evidence to support the molecular mechanism
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for ASXL2-mediated BAP1 deubiquitinase activity. ASXL functions as a molecular
scaffold though its AB box to recruit the ULD domain of BAP1 to transcription factors,
which specifically bind to its target genes. Then the UCH catalytic domain of BAP1
ubiquitin hydrolase specifically removes the ubiquitin from histones on chromatin to
regulate target genes. ASXL2 not only functions as a molecular scaffold for BAP1 but
also greatly stimulates its enzymatic activity. Loss of binding to ASXL2 would
dramatically decrease BAP1 deubiquitination activity and thereby lead to BAP1
dependent alterations in chromatin state/gene expression in human cancers and other
diseases. Furthermore, small-molecule approaches to reactivate latent wild-type UCH
activity of these mutants occurring in a subset of BAP1-mutant cancers might be
therapeutically viable.
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APPENDICES
Appendix A: Materials and Methods for the molecular mechanisms of the
EMTosome

Cloning and Vectors

All cloning was done by PCR amplification and subcloned into the respective
plasmids. The pCDNA3.1-Sox9-C-Flag was acquired from Genescript and used as the
template

for

cloning

GST-Sox9/DIM+HMG

(Forward

primer

5’

–

ATACGCGGATCCAATCTCCTGGACCCCTTCAT – 3’ and reverse primer 5’ –
ATTCCGGGATTCTCAGATGTGCGTCTGCTCCGTG – 3’) into pGEX4T1 plasmid and
His-Sox9/DIM+HMG

primer

(Forward

CGCGGATCCAATCTCCTGGACCCCTTCATG

–

3’

5’

and

reverse

–

primer

5’

–

CCCAAGCTTTCAAGGTCGAGTGAGCTGTGT – 3’) into pQE30 plasmid. pCDNA3.1Snail-C-Flag and pCDNA3.1-HA-Snail were from our laboratory and used as a template
for cloning His-SnailZF1-4 (Forward primer 5’ – TCGCACACGTGCCTTGTGTCTGCA –
3’ and reverse primer 5’ – CTGCTAAGTCGCTCCCGGAGGCCT – 3’) into pQE30
plasmid. pGEX4T1-SnailZF1-4 (GST-SnailZF1-4) was from our laboratory (described
earlier). The pCDNA3.1-Twist and pQE-Twist were as previously described (12) and
used

as

the

template

for

cloning

GST-WR

(Forward

primer

5’

-

ATCATAGGATCCAGCTGCAGCTATGTGGCTCAC – 3’ and reverse primer 5’ ATGCTGAAGCTTTTAGTGAGATGCGCTCATGGAC – 3’) into pGEX4T1 plasmid, dual
expressed

His-Twist/bHLH+WR

(Forward

primer

5’

-

ATCATAGGATCCACAGTCTTACGAGGAGCTCCAA – 3’ and reverse primer 5’ 65

ATGCTGAAGCTTTTAGTGAGATGCGCTCATGGAC – 3’) into pETDuet plasmid, first
cloning

site,

and

His-Twist/bHLHΔWR

(Forward

primer

5’

-

ATCATAGGATCCACAGTCTTACGAGGAGCTCCAA – 3’ and reverse primer 5’ ATGCTGAAGCTTCTAATCCAGCTCATCAGACTGCAG – 3’) into pETDuet plasmid, first
cloning site. The pCDNA3.1-E47/bHLH was as previously stated (12) and used as the
template

for

cloning

dual

expressed

E47/bHLH

(Forward

primer

5’

-

ATCATAAGATCTCTGTCCCTGGAGGAGAAAGAC – 3’ and reverse primer 5’ ATGCTGCTCGAGCTAATTCAGGTTCCGCTCTCGCAC – 3’) into pETDuet plasmid,
second cloning site.

Cell Culture and transfections

Sum1315 cells were acquired from the Zhou lab at the University of Kentucky,
and originally developed by Rosenblatt lab (27) and were cultured in F-12 media (Gibco
11765-047) supplemented with 5% FBS (Corning MT35-010-CV), 2mM Glutamine
(Corning 25-005-CI), 50units/mL Pen Strep (Gibco 15140-122), 10 ng/mL EGF (Corning
354001), 5 μg/mL Insulin (Gibco 51500-056). Cos-1 cells were acquired from ATCC and
cultured in DMEM (Corning 10-017-CV) supplemented with 10% FBS (Corning MT35010-CV), 2mM Glutamine (Corning 25-005-CI), and 50units/mL Pen Strep (Gibco 15140122). Transfections were done with pCDNA3.1 recombinant plasmid.

Prior to

transfection, Cos-1 cells were grown to 80-90% confluency in 15cm tissue culture dishes
and media was changed to Pen Strep free media 12-16 hours before transfection.
Before transfection, media was changed to Opti-mem, with no additives. Transfections
were done using Lipofectamine 2000 (Invitrogen 11668-019). For single transfections,
20μg of DNA was used. For triple transfections, 24μg DNA was used, 8μg of each
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plasmid. For quadruple transfections 24μg of DNA was used, 6μg of each plasmid. DNA
being transfected was mixed in 1.5mL Opti-mem and incubated for 5 min at 25°C. 60uL
of Lipofectamine was mixed with 1.5mL Opti-mem and incubated for 5 min at 25°C.
DNA and Lipofectamine Opti-mem were then mixed and incubated for 30 minutes at
25°C.

Then the Lipofectamine/DNA mixture was added to the cell cultures and

incubated for 4 hours at 37°C in incubator. Media was changed back to Pen Strep free
media and incubated for 48 hours.

Nuclear extracts were then made utilizing the

provided nuclear extract protocol.

Nuclear Extracts and Whole Cell Lysates

For nuclear extracts, cells were cultured to 90% confluency in 15cm dishes. All
steps were performed at 4°C. Cells were rinsed four times with 5mL PBS. 10 mL of
Lysis Buffer (10mM HEPES, 10mM NaCl, 1.5mL MgCl2, 20% Glycerol, 0.2mM EDTA,
0.1% Triton X-100, 1mM DTT, 1mM PMSF, 10µg/μL pepstatin, 10μg/µL leupeptin,
10μg/µL aprotinin, 2mM Sodium Ortho-vanadate) was added and incubated for 2
minutes on ice. Cells were scraped and incubated 4 minutes on ice. Following that,
cells were scraped into 50mL conical tubes and centrifuged at 500g for 10 minutes at
4°C.

Supernatant was removed and pellets were resuspended in 1mL of Nuclear

Extract Buffer (10mM HEPES, 500mM NaCl, 1.5mL MgCl2, 20% Glycerol, 0.2mM EDTA,
0.1% Triton X-100, 1mM DTT, 1mM PMSF, 10μg/μL pepstatin, 10μg/μL leupeptin,
10μg/μL aprotinin, 2mM Sodium Ortho-vanadate). Pellet was resuspended by gentle
pipetting 60 times, incubated on ice 5 minutes, then gentle pipetting 40 times. The
resuspended extract was rotated at 4°C for 90 minutes, followed by centrifugation at 13k
RPM for 30 minutes. Extracts were then dialyzed into binding buffer (20mM HEPES,
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100mM KCl, 1mM DTT, 10% Glycerol), aliquoted into 100μL portions and snap frozen.
40μ of nuclear extract was run on Western blot. Whole cell lysates were made by
harvesting and lysing cells in a 10cm dish (80-90% confluency) in 100 μl of Tween 20
Lysis Buffer (61)(25 mM Tris/Hepes, pH 8.0, 25 mM NaCl, 2 mM EDTA, 1 mM PMSF,
0.5% Tween 20). Lysate was incubated on ice for 15 minutes and the volume was
estimated. 1/5 volume of 5 x Buffer was added to lyse the nuclei. The final concentration
of the lysis buffer is 1% Triton x100, 20 mM Tris, pH 8.0, 150 mM NaCl, 10 mM MgCl2, 2
mM EDTA, 10% Glycerol, 2.5 mM β-mercaptoethanol, 1 mM NaF, 1 mM DTT, 1 mM
PMSF. Lysate was incubated on ice for 15 min, then centrifuged at 13k RPM for 10 min
and the supernatant was recovered. 5 μl of supernatant was removed to check protein
concentration by Bradford assay and 100 μg of whole cell lysate was used to do
Western blot.

Protein Expression and purification

For native purification, pETDuet-Twist-E47 plasmids were transformed into
Rosetta2(DE3)-pLysS (Millipore) bacteria. Colonies were selected and grown in 2YT
media 24 hours, and then used to start fresh cultures in 800mL of 2YT at OD 600 of 0.10.2. These cultures were grown to OD600 0.6-0.8 then protein production was induced
with 500μM isopropyl-1-thio-β-D-galactopyranoside (IPTG) and induction was done 1216 hours at 20C. Cultures were harvested by centrifugation and resuspended in 40mL
of sonication buffer (50mM sodium phosphate pH 8.0, 500mMNaCl, 5 mM imidazole,
1mM PMSF, 500μM TCEP, 0.5% Tween-20, 10μg/mL DNaseI, 150μg/mL Lysozyme).
Supernatant was sonicated for 3 minutes, 3x on ice (Branson Sonifier 450, 80% power,
100% duty) and centrifuged 12k RPM for 30 minutes at 4°C to clarify. Supernatant was
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bound to 500μL TALON Metal Affinity Resin (Takara 635501) pre-equilibrated in
sonication buffer, by rotating at 4°C for 1 hour. Beads were then washed 4x with 10mL
Wash buffer (50mM sodium phosphate pH 8.0, 500mMNaCl, 20 mM imidazole, 1mM
PMSF, 500μM TCEP, 0.5% Tween-20). Protein was eluted from beads with elution
buffer (50mM sodium phosphate pH 8.0, 500mMNaCl, 1M Imidazole). Eluted protein
was then dialyzed in 4L SEC buffer (25mM HEPES pH 7.5, 200mM NaCl, 500μM TCEP)
twice, 2 hours each, and then once 12-16 hours, all at 4°C.

Protein was then

concentrated to ~20mg/mL using centrifugal concentrators (Amicon Ultra-15 3k NMWL
UFC900324) and run on FPLC (AKTA Pure) for size exclusion chromatography (SEC
column used is Superdex 75) and 1mL fractions were collected. After analyzing all
fractions by SDS-Page, fractions 10 and 11 were collected and pooled as purified
proteins. Expression of pQE plasmids, denaturing purifications, and refolding were done
as previously described (12). GST-Fusion proteins were purified as previously described
(62).

Electrophoretic motility shift assays (EMSA)

Protocol for EMSAs, oligonucleotide annealing, probe labeling, and probes used
are previously described (11), except as follows.

The A2M DNA probe used is

comprising the -2512 to -2531 promoter region of the human A2M gene, with a CG
added to each end to provide additional stability.

The 5’ to 3’ sequence is 5’ -

GCTCAGATGGAAGCCATGTGTGC - 3’, with the binding regions, E-boxes, underlined.
The Mut1 and Mut2 mutations are as previously described (11). The double mutant (Dbl
Mut) probe was comprised of both E-box mutations.

Antibody shifts were done by

incubating the protein/extract with 4uL of antibody (α-Twist: Invitrogen PA5-47824, α69

Snail: Santa Cruz E-18, α-Sox9: Abcam ab3667, α-E47: BD Pharmingen 554077) for 15
minutes at 25°C before adding radiolabeled probe. Equilibrium competition was done by
mixing labeled and unlabeled competitor together and incubating for 15 minutes at 25°C
prior to addition of extract/proteins. Order of addition competition was done by adding
the unlabeled competitor after binding of protein to DNA, and then incubating for 30
minutes at 30°C. The competitor probes were as follows, 5’ to 3’, with the binding
regions underlined, E-cad 5’- GTGGCCGGCAGGTGAACCCTCA - 3’, Sox9 5’CCAGGACAATGCCGCCATTGTCCTGG

-

3’,

SZF

5’

–

GATCCCAGGGTAACAGCCGTTTG – 3’.

Immunoprecipitation and Western Blot

Immunoprecipitations and Western Blots were done as previously described
except as noted below (55). Addition of oligonucleotides to NE increased affinity to flag
antibody resin. 5μL of oligonucleotide (2mg/mL) and 10uL of dI: dC (1μg/μL) was added
to each 1mL of nuclear extract, and then incubated at 30°C for 30min at 120 rpm.
Affinity beads [Anti-Flag M2 affinity gel (Sigma A2220), Anti-Myc (Pierce 20169), Anti-HA
(ICL RGHT-145D)] was pre-washed in BB buffer (20mM HEPES, 100mM KCl, 1mM
DTT, 10% Glycerol) twice, and 1mL of nuclear extract was bound to 200μL of 50/50
slurry by rotating for 2 hours at 4°C. Resin was then washed five times with BB buffer.
Protein was eluted twice from resin using 100μL of 500ng/μL [3x flag peptide (Sigma
F4799), Myc (Pierce 20170), HA (Thermo Scientific 26184), respectively] by incubating
at 37°C for 20 minutes shaking at 150rpm, and then supernatant separated from beads
using centrifuge columns (Pierce 89868). Primary antibodies used for Western Blots
were α-Twist (Santa Cruz 2C1A), α-Snail (Abcam ab63371), α-Slug (Cell Signaling
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C19G7), α-E47 (BD Pharmingen 554077), α-E12/E47 (BD Pharmingen 554199), αVimentin (Cell Signaling 5G3F10). Primary antibodies used are at 1:1000 dilution unless
specified. Secondary antibodies are HRP conjugated α-mouse (7076), α-rabbit (7074),
or α-rat (7077) from Cell Signaling, used at 1:5000.

GST binding assays, Biotinylated Affinity Chromatography

GST association assays were performed as previously described (Peng, JBC,
2000) except as noted below. Binding was done at 37°C instead of room temperature.
Wash steps were performed with the buffers BB200 (200mM NaCl, 20mM Tris pH 7.5,
10% glycerol), BB500 (500mM NaCl, 20mM Tris pH 7.5, 10% glycerol), and RIPA
(10mM Tris pH7.4, 150mM NaCl, 1% Triton X-100, 1% DOC, 0.1% SDS). Antibodies
used were the same as for Western Blots. For biotinylated affinity chromatography, the
same DNA probes were used as in EMSA, except for biotin being attached to the 5’ end
of the DNA oligonucleotide (-2531 in relation to transcription start site). Streptavidin
beads (Invitrogen Dynabeads M-280 Streptavidin– 10μL bead volume) were equilibrated
in binding buffer previously described under nuclear extracts, by rotating for 5 minutes at
25°C. Supernatant was removed and binding buffer was added to a volume of 1mL, and
biotinylated DNA (30μL of 20μM) and BSA (5μL of 200mg/mL) were added, then rotated
for 1 hour at 25°C. During this time, extracts were incubated with dI: dC (4μL of 1μg/μL
in 400μL of nuclear extract) and incubated for 30 minutes at 30°C. Supernatant for DNA
binding to beads was removed, 600uL of binding buffer and extracts were then added to
beads and incubated by rotating for 1 hour at 25°C. Beads were washed four times with
binding buffer plus 0.2% NP40, rotating 5 minutes at 25°C for each.
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Beads were

resuspended in 50uL of 1x Laemmli buffer and visualized by SDS-PAGE and Western
Blot (α-Twist 2C1A, α-Snail L70G2, α-Sox9 Abcam ab3679).

Chromatin Immunoprecipitation

COS-1 Cells were grown to 90% confluency in 15cm dishes and transfected as
described in this manuscript. Cells were fixed with 1% Formaldehyde for 5 minutes at
25°C, then quenched with 125mM glycine for 5 minutes at 25°C. Hells were harvested
and the chromatin was enriched in chromatin enrichment buffer (20mM Tris HCl (pH
8.0), 0.25% Triton X-100, 200mM NaCl, 10mM EDTA, 0.5mM EGTA, 1ug/mL Protease
inhibitors [aprotinin, leupeptin, pepstatin], 1mM Benzamidine, 50mM NaF, 10mM
NaOV3, 5mM butyric acid) for 10 minutes at 4°C. Cells were pelleted (5.0x106 cells per
1mL) and resuspended in IP Buffer (20mM Tris pH 8.0, 0.05% DOC, 0.5% Triton X-100,
0.5% NP-40, 200mM NaCl, 5mM butyrate, and Protease Inhibitors), then sonicated to a
peak of 200-500bp (Branson Sonifier 450, in ice bath, 80% power, 30 seconds
sonication, 30 seconds incubating on ice, 10 minutes total sonication time). Chromatin
was precleared with Protein A/ beads (20uL per 1mL), which were pre-blocked with
salmon sperm DNA and BSA, for 1 hour at 25°C. 1mL of Chromatin was incubated 1216 hours at 4°C with 10μg of antibody (α-RNA Pol2 [sera from Gardini lab], α-Twist
[Abcam ab50887], α-Snail [R&D Systems AF3639], α-Sox9 [Abcam ab3697], Normal
mouse IgG [Santa Cruz sc-2025]). Immune complexed were bound to 20uL pre-blocked
Protein A/G Beads at 4°C for 3 hours. Washes were: 4x with IP Buffer, 2x with High Salt
IP Buffer (400mM NaCl), 1x with LiCl buffer (10mM Tris pH 8.0, 250mM LiCl, 0.5%
NP40, 1% Triton X-100, 0.1% DOC, 5mM EDTA, and PIs), 1x with Mixed Mycelle wash
buffer (20mM Tris pH 8.1, 150mM NaCl, 5mM EDTA, 5% Sucrose, 1% Triton X-100,
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0.2% SDS), 2x with TE. Elution was done with 250μL 50mM Tris (pH 8.0), 200mM
NaCl, 5mM EDTA, 1% SDS on thermomixer at 37C for 30 minutes, twice. Crosslinks
were reversed 12-16 hours at 65°C, then treated with 30ug of Proteinase K (Roche) at
55°C for two hours. DNA was purified by phenol/chloroform extraction and analyzed by
standard PCR. A2M PCR Primers are: forward probe 5’-CTCTGTCACATAAAGGTCCC3’, reverse probe 5’-AAGGGTACAGTTCTGCGCTT-3’. E-cad PCR Primers are: forward
probe

5’-TAGAGGGTCACCGCGTCTAT-3’,

reverse

probe

5’-

TCACAGGTGCTTTGCAGTTC-3’.

Appendix B: Materials and Methods for the regulation of BAP1

Plasmids

The pFastBacTHa-BAP1-FL-WT, -BAP1-UCH-WT and -UCH-C91S mutant
plasmids, pGEX-2TK-BAP1-UCH-WT (1-250 aa), pGEX-4T-1-BAP1-ULD, pQE30-BAP1ULD (601-729aa) and pQE30-ASXL2-AB (261-381aa) plasmids were previously
described (55). The pETDuet-1-His-BAP1-ULD+ASXL2-AB plasmid was constructed
through PCR-based cloning and was sequenced to confirm its authenticity.

Proteins expression and purification; GST binding assays

The baculovirus (Bv) Bv-His-BAP1-FL-WT, Bv-His-BAP-UCH-WT and Bv-UCHC91S mutant proteins were expressed in Bv-infected Sf9 cells and purified as previously
described (55). The GST- and His-tagged BAP1 and ASXL2 proteins were expressed in
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E. coli BL21 (DE3) (Stratagene) and SG13009 (S9) (Qiagen), respectively. The
pETDuet-1-His-BAP1-ULD+ASXL2-AB protein complex was expressed in Rosetta 2
(DE3) pLysS (Millipore). The bacteria bearing the desired plasmids were propagated
with aeration at 37C in 1L of 2YT to an A600 absorbance of approximately 0.6. IPTG was
added to 1 mM, and growth was continued at 20C overnight. The cells were harvested
by centrifugation.
GST-fusion proteins were purified as described previously (63). The bacterial
His-tagged proteins were purified under denaturing conditions (Qiagen) and refolded by
dialysis as described previously (63). The recombinant human BAP1-FL-WT protein was
purchased from Boston Biochem (E-345-050). The Duet-His-ULD/AB protein complex
was purified under native purification conditions using Cobalt beads (Talon), followed by
dialysis and concentration to desired concentration. GST association assays were
performed as described previously (62) using BB200 buffer (200 mM NaCl, 20 mM Tris,
pH 7.5, 0.2 mM EDTA, 10% Glycerol, 1 mM PMSF and 0.2% NP40) and BB500
(containing the same components as BB200 except that the concentration of NaCl was
500 mM).

Dynamic light scattering (DLS)

DLS was measured using DynaPro Titan (Wyatt Technology). Purified His-BAP1ULD, His-AB and His-ULD/AB complex were in buffer containing 50 mM potassium
phosphate, pH 7.5, 200 mM potassium chloride and 1mM TCEP. His-ULD was
measured at 574 µM concentration. His-AB was measured at 77 µM concentration. The
His-ULD/AB protein complex was measured at 70 µM concentration. Samples were
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spun in a tabletop microcentrifuge at 13,000 rpm for 10 minutes prior to measurements,
and measurements were done at 10°C.

Isothermal titration calorimetry (ITC)

ITC was performed using Microcal ITC 200 (Microcal/Malvern Instruments). HisULD and His-AB proteins were dialyzed in 50 mM potassium phosphate, pH 7.5, 200
mM potassium chloride, and 1 mM TCEP. His-AB was placed in the sample cell at
concentration 77 µM. His-ULD was titrated into the sample cell at a concentration of 574
µM. Two references were used. The first reference was titration of the buffer into His-AB
protein. The second reference was titration of His-ULD protein into the buffer. Both
reference values were subtracted from the experimental data. ITC calculations and fitting
were performed with Origin 7 software, using autofit, 200 iterations. Based on the
results, the stoichiometry and binding kinetics of the proteins were determined. The
direct measurements of binding affinity (K a), enthalpy changes (ΔH) and binding
stoichiometry (n) were used to determine the Gibbs free energy changes (ΔG) and
entropy changes (ΔS) using ΔG=-RTlnKa= ΔH-TΔS (R = gas constant; T = absolute
temperature). Dissociation constant (Kd) is 1/Ka. Experiments were performed in
duplicate.

No uncertainty ranges are given due to the low number of technical

replicates.

Kinetic analysis: surface plasmon resonance (SPR)

Interactions between the ASXL-AB and BAP1-ULD domains were studied by
SPR using a Biacore T200 instrument. GST-antibody (Abcam ab9085) was coupled to
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all flow cells of a CM5 sensor chip using standard amine coupling procedures in a
HEPES-buffered saline running buffer. After coupling of the GST antibody, the running
buffer was changed to 25 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM DTT and 0.05%
Tween20. GST-ULD was immobilized onto the chip surface at a ligand density of 400
RU, followed by a 120-s stabilization period. A single concentration His-AB was then
injected over both the reference cell, with GST antibody alone, and the flow cell covered
with GST-ULD at 30 µL/min. The binding reaction was monitored for 240 s followed by a
300-s dissociation time. Specific binding was determined by subtracting the refractive
index change in the reference cell from the flow cell containing GST-ULD. After each
concentration of His-AB, the GST-ULD was stripped from the surface using a 60-s
injection of 20 mM glycine, pH 2.0 at 30 µL/min, followed by another 120-s stabilization
period. Fresh GST-ULD was then immobilized as above. Experiments were done in
triplicate.
Interactions between the His-ULD/AB complex and full-length BAP1 or the BAP1UCH domain were also studied using the Biacore T200 instrument. Full-length HisBAP1, GST-UCH, or GST alone was directly immobilized to a CM5 sensor chip at a
density of ~3000 RU using standard amine coupling procedures. The running buffer for
the binding studies was 25 mM HEPES, pH 7.4, 250 mM NaCl, 5 mM DTT and 0.05%
Tween20. The higher NaCl concentration was required to reduce nonspecific binding to
the reference cell in the absence of protein. Various concentrations of His-ULD/AB
complex were injected over the flow cells at 30 µL/min and the binding reaction
monitored for 90 s followed by a 240-s dissociation time. Specific binding was
determined by subtracting the refractive index change in the reference cell from the
readings of the other three flow cells. After the 240-s dissociation time, most of the HisULD/AB complex was completely dissociated. However, 1 M NaCl at 30 µL/min was
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injected for 60 s over the flow cells to clear any remaining bound protein. Experiments
were done in triplicate.

Sequence and structure analysis

Open reading frame sequences for BAP1, UCHL1, UCHL3, UCHL5, ASXL1,
ASXL2, and ASXL3 were obtained from NCBI for vertebrate species. Separately, the
UCH or ASX sequences were aligned and codon selection scored using our previously
published metrics (PMID: 28204942). COSMIC variants (PMID: 25355519) for BAP1
were extracted on June 20, 2018. Secondary structure predictions for proteins were
performed using http://cib.cf.ocha.ac.jp/bitool/MIX/, a combination of Chou-Fasman,
GOR, and Neural Network predictions. Conservation was highlighted onto the human
protein model generated from PDB 6cga.

77

BIBLIOGRAPHY
1.

Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science.

2011;331(6024):1559-64.
2.

Dillekas H, Rogers MS, Straume O. Are 90% of deaths from cancer caused by

metastases? Cancer Med. 2019;8(12):5574-6.
3.

Group USCSW. U.S. Cancer Statistics Data Visualizations Tool, based on

November 2018 submission data (1999-2016) 2019 [updated June 2019. Available from:
www.cdc.gov/cancer/dataviz.
4.

Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat

Med. 2006;12(8):895-904.
5.

Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis.

Molecular oncology. 2017;11(1):28-39.
6.

Du B, Shim JS. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome

Drug Resistance in Cancer. Molecules. 2016;21(7).
7.

Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour

progression: an alliance against the epithelial phenotype? Nature reviews Cancer.
2007;7(6):415-28.
8.

Zhang P, Hu P, Shen H, Yu J, Liu Q, Du J. Prognostic role of Twist or Snail in

various carcinomas: a systematic review and meta-analysis. European journal of clinical
investigation. 2014;44(11):1072-94.
9.

Tang H, Massi D, Hemmings BA, Mandala M, Hu Z, Wicki A, et al. AKT-ions with

a TWIST between EMT and MET. Oncotarget. 2016;7(38):62767-77.
10.

Roschger C, Cabrele C. The Id-protein family in developmental and cancer-

associated pathways. Cell communication and signaling : CCS. 2017;15(1):7.

78

11.

Chiang C, Ayyanathan K. Snail/Gfi-1 (SNAG) family zinc finger proteins in

transcription regulation, chromatin dynamics, cell signaling, development, and disease.
Cytokine & growth factor reviews. 2013;24(2):123-31.
12.

Chang AT, Liu Y, Ayyanathan K, Benner C, Jiang Y, Prokop JW, et al. An

evolutionarily conserved DNA architecture determines target specificity of the TWIST
family bHLH transcription factors. Genes & development. 2015;29(6):603-16.
13.

Wang Y, Shi J, Chai K, Ying X, Zhou BP. The Role of Snail in EMT and

Tumorigenesis. Current cancer drug targets. 2013;13(9):963-72.
14.

Wu Y, Zhou BP. Snail: More than EMT. Cell adhesion & migration.

2010;4(2):199-203.
15.

Olmeda D, Jorda M, Peinado H, Fabra A, Cano A. Snail silencing effectively

suppresses tumour growth and invasiveness. Oncogene. 2007;26(13):1862-74.
16.

Hou L, Srivastava Y, Jauch R. Molecular basis for the genome engagement by

Sox proteins. Seminars in cell & developmental biology. 2017;63:2-12.
17.

Huang J, Guo L. Knockdown of SOX9 Inhibits the Proliferation, Invasion, and

EMT in Thyroid Cancer Cells. Oncology research. 2017;25(2):167-76.
18.

Kondratyeva LG, Sveshnikova AA, Grankina EV, Chernov IP, Kopantseva MR,

Kopantzev EP, et al. Downregulation of expression of mater genes SOX9, FOXA2, and
GATA4 in pancreatic cancer cells stimulated with TGFbeta1 epithelial-mesenchymal
transition. Doklady Biochemistry and biophysics. 2016;469(1):257-9.
19.

Gu S, Boyer TG, Naski MC. Basic helix-loop-helix transcription factor Twist1

inhibits transactivator function of master chondrogenic regulator Sox9. The Journal of
biological chemistry. 2012;287(25):21082-92.
20.

Choi BJ, Park SA, Lee SY, Cha YN, Surh YJ. Hypoxia induces epithelial-

mesenchymal transition in colorectal cancer cells through ubiquitin-specific protease 4779

mediated stabilization of Snail: A potential role of Sox9. Scientific reports.
2017;7(1):15918.
21.

Laughney AM, Hu J, Campbell NR, Bakhoum SF, Setty M, Lavallee VP, et al.

Regenerative lineages and immune-mediated pruning in lung cancer metastasis. Nat
Med. 2020;26(2):259-69.
22.

Lefebvre V, Dvir-Ginzberg M. SOX9 and the many facets of its regulation in the

chondrocyte lineage. Connect Tissue Res. 2017;58(1):2-14.
23.

Lefebvre V, Angelozzi M, Haseeb A. SOX9 in cartilage development and

disease. Curr Opin Cell Biol. 2019;61:39-47.
24.

Grigore AD, Jolly MK, Jia D, Farach-Carson MC, Levine H. Tumor Budding: The

Name is EMT. Partial EMT. Journal of clinical medicine. 2016;5(5).
25.

Jolly MK, Ware KE, Gilja S, Somarelli JA, Levine H. EMT and MET: necessary or

permissive for metastasis? Molecular oncology. 2017;11(7):755-69.
26.

Saitoh M. Involvement of partial EMT in cancer progression. Journal of

biochemistry. 2018;164(4):257-64.
27.

Moreau JE, Anderson K, Mauney JR, Nguyen T, Kaplan DL, Rosenblatt M.

Tissue-engineered bone serves as a target for metastasis of human breast cancer in a
mouse model. Cancer research. 2007;67(21):10304-8.
28.

Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like

cells that self-renew, give rise to phenotypically diverse progeny and survive
chemotherapy. Breast Cancer Res. 2008;10(2):R25.
29.

DiMeo TA, Anderson K, Phadke P, Fan C, Perou CM, Naber S, et al. A novel

lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelialmesenchymal transition in basal-like breast cancer. Cancer research. 2009;69(13):536473.
80

30.

Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, et al. A twist code

determines the onset of osteoblast differentiation. Developmental cell. 2004;6(3):423-35.
31.

Lander R, Nasr T, Ochoa SD, Nordin K, Prasad MS, Labonne C. Interactions

between Twist and other core epithelial-mesenchymal transition factors are controlled by
GSK3-mediated phosphorylation. Nature communications. 2013;4:1542.
32.

Mladinich M, Ruan D, Chan CH. Tackling Cancer Stem Cells via Inhibition of

EMT Transcription Factors. Stem cells international. 2016;2016:5285892.
33.

Aiello NM, Kang Y. Context-dependent EMT programs in cancer metastasis. The

Journal of experimental medicine. 2019;216(5):1016-26.
34.

Marie PJ, Kaabeche K, Guenou H. Roles of FGFR2 and twist in human

craniosynostosis: insights from genetic mutations in cranial osteoblasts. Frontiers of oral
biology. 2008;12:144-59.
35.

Tseng JC, Chen HF, Wu KJ. A twist tale of cancer metastasis and tumor

angiogenesis. Histology and histopathology. 2015;30(11):1283-94.
36.

Gheldof A, Berx G. Cadherins and epithelial-to-mesenchymal transition. Progress

in molecular biology and translational science. 2013;116:317-36.
37.

Soo K, O'Rourke MP, Khoo PL, Steiner KA, Wong N, Behringer RR, et al. Twist

function is required for the morphogenesis of the cephalic neural tube and the
differentiation of the cranial neural crest cells in the mouse embryo. Developmental
biology. 2002;247(2):251-70.
38.

Vincentz JW, Firulli BA, Lin A, Spicer DB, Howard MJ, Firulli AB. Twist1 controls

a cell-specification switch governing cell fate decisions within the cardiac neural crest.
PLoS genetics. 2013;9(3):e1003405.

81

39.

McIntosh LP, Dahlquist FW. Biosynthetic incorporation of 15N and 13C for

assignment and interpretation of nuclear magnetic resonance spectra of proteins. Q Rev
Biophys. 1990;23(1):1-38.
40.

Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, et al.

BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances
BRCA1-mediated cell growth suppression. Oncogene. 1998;16(9):1097-112.
41.

Nishikawa H, Wu W, Koike A, Kojima R, Gomi H, Fukuda M, et al. BRCA1-

associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. Cancer
Res. 2009;69(1):111-9.
42.

Misaghi S, Ottosen S, Izrael-Tomasevic A, Arnott D, Lamkanfi M, Lee J, et al.

Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle
regulator host cell factor 1. Molecular and cellular biology. 2009;29(8):2181-92.
43.

Gaytan de Ayala Alonso A, Gutierrez L, Fritsch C, Papp B, Beuchle D, Muller J.

A genetic screen identifies novel polycomb group genes in Drosophila. Genetics.
2007;176(4):2099-108.
44.

Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK,

Fraterman S, et al. Histone H2A deubiquitinase activity of the Polycomb repressive
complex PR-DUB. Nature. 2010;465(7295):243-7.
45.

Inobe T, Matouschek A. Paradigms of protein degradation by the proteasome.

Current opinion in structural biology. 2014;24:156-64.
46.

Isaksson A, Musti AM, Bohmann D. Ubiquitin in signal transduction and cell

transformation. Biochimica et biophysica acta. 1996;1288(1):F21-9.
47.

Kadariya Y, Cheung M, Xu J, Pei J, Sementino E, Menges CW, et al. Bap1 Is a

Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying
Heterozygous Germline Bap1 Mutations. Cancer research. 2016;76(9):2836-44.
82

48.

Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear

deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses
in malignant pleural mesothelioma. Nature genetics. 2011;43(7):668-72.
49.

Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al.

Frequent

mutation

of

BAP1

in

metastasizing

uveal

melanomas.

Science.

2010;330(6009):1410-3.
50.

Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline

BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):10225.
51.
G,

Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru
et

al.

Germline

BAP1

mutation

predisposes

to

uveal

melanoma,

lung

adenocarcinoma, meningioma, and other cancers. Journal of medical genetics.
2011;48(12):856-9.
52.

Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and

cancer. Nature reviews Cancer. 2013;13(3):153-9.
53.

Pilarski R, Rai K, Cebulla C, Abdel-Rahman M. BAP1 Tumor Predisposition

Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K,
et al., editors. GeneReviews((R)). Seattle (WA)2016.
54.

Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, et al. Germline

mutations

in

BAP1

predispose

to

melanocytic

tumors.

Nature

genetics.

2011;43(10):1018-21.
55.

Peng H, Prokop J, Karar J, Park K, Cao L, Harbour JW, et al. Familial and

Somatic BAP1 Mutations Inactivate ASXL1/2-Mediated Allosteric Regulation of BAP1
Deubiquitinase

by

Targeting

Multiple

Independent

2018;78(5):1200-13.
83

Domains.

Cancer

Res.

56.

Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, et al. ASXL1

mutations promote myeloid transformation through loss of PRC2-mediated gene
repression. Cancer cell. 2012;22(2):180-93.
57.

Bainbridge MN, Hu H, Muzny DM, Musante L, Lupski JR, Graham BH, et al. De

novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with
similarities to Bohring-Opitz syndrome. Genome medicine. 2013;5(2):11.
58.

Hoischen A, van Bon BW, Rodriguez-Santiago B, Gilissen C, Vissers LE, de

Vries P, et al. De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome.
Nature genetics. 2011;43(8):729-31.
59.

Argote A, Mora-Hernandez O, Milena Aponte L, Barrera-Chaparro DI, Munoz-

Ruiz LM, Giraldo-Mordecay L, et al. Cardiovascular Risk Factors and Carotid IntimaMedia Thickness in a Colombian Population With Psoriasis. Actas dermo-sifiliograficas.
2017;108(8):738-45.
60.

Foglizzo M, Middleton AJ, Burgess AE, Crowther JM, Dobson RCJ, Murphy JM,

et al. A bidentate Polycomb Repressive-Deubiquitinase complex is required for efficient
activity on nucleosomes. Nat Commun. 2018;9(1):3932.
61.

Klenova E, Chernukhin I, Inoue T, Shamsuddin S, Norton J. Immunoprecipitation

techniques for the analysis of transcription factor complexes. Methods. 2002;26(3):2549.
62.

Peng H, Begg GE, Harper SL, Friedman JR, Speicher DW, Rauscher FJ, 3rd.

Biochemical analysis of the Kruppel-associated box (KRAB) transcriptional repression
domain. J Biol Chem. 2000;275(24):18000-10.
63.

Peng H, Begg GE, Schultz DC, Friedman JR, Jensen DE, Speicher DW, et al.

Reconstitution of the KRAB-KAP-1 repressor complex: a model system for defining the

84

molecular

anatomy

of

RING-B

box-coiled-coil

domain-mediated

interactions. Journal of molecular biology. 2000;295(5):1139-62.

85

protein-protein

